



**European Stroke Organisation (ESO) Guideline on
pharmacological interventions for long-term secondary
prevention after ischaemic stroke or transient ischaemic
attack**

Journal:	<i>European Stroke Journal</i>
Manuscript ID	ESO-22-0078.R2
Manuscript Type:	Guideline
Date Submitted by the Author:	24-Apr-2022
Complete List of Authors:	<p>Dawson, Jesse; University of Glasgow Institute of Cardiovascular and Medical Sciences</p> <p>Bejot, Yannick; University Hospital of Dijon, Neurology</p> <p>Christensen, Louisa; Bispebjerg Hospital, Department of neurology</p> <p>De Marchis, Gian Marco; University Hospital Basel and University of Basel, Neurology and Stroke Center</p> <p>Dichgans, Martin; Institute for Stroke and Dementia Research (ISD),</p> <p>Hagberg, Guri; Vestre Viken Hospital Trust, Baerum Hospital, Dept. of Medical Research</p> <p>Heldner, Mirjam; Inselspital University Hospital Bern, Stroke Research Center Bern</p> <p>Milionis, Haralambos; University of Ioannina School of Medicine, Department of Medicine</p> <p>Li, Linxin; University of Oxford Centre for Prevention of Stroke and Dementia</p> <p>Pezzella, Francesca; San Camillo Forlanini Hospital, Department of Neuroscience</p> <p>Taylor-Rowan, Martin; University of Glasgow Institute of Cardiovascular and Medical Sciences</p> <p>Tiu, Cristina; Carol Davila University of Medicine and Pharmacy</p> <p>Webb, Alastair; University of Oxford, Wolfson Centre for Prevention of Stroke and Dementia, Department of Clinical Neurosciences</p>
Keywords:	guideline, systematic review, stroke, hypertension, diabetes, anti platelet, dyslipidaemia
Abstract:	<p>Recurrent stroke affects 9-15% of people after 1 year. This European Stroke Organisation (ESO) guideline provides evidence-based recommendations on pharmacological management of blood pressure (BP), diabetes mellitus, lipid levels and antiplatelet therapy for the prevention of recurrent stroke and other important outcomes in people with ischaemic stroke or transient ischaemic attack (TIA). It does not cover interventions for specific causes of stroke, including treatment of cardioembolic stroke, which are addressed in other guidelines. This guideline was developed through ESO standard operating procedures and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology. The working group identified clinical questions, selected outcomes, performed systematic reviews, with meta-analyses where appropriate, and made evidence-based recommendations, with expert consensus statements where evidence</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>was insufficient to support a recommendation. To reduce the long-term risk of recurrent stroke or other important outcomes after ischaemic stroke or TIA, we recommend: BP lowering treatment to a target of <130/80 mmHg, except in subgroups at increased risk of harm; HMGCoA-reductase inhibitors (statins) and targeting a low density lipoprotein level of <1.8 mmol/l (70 mg/dl); avoidance of dual antiplatelet therapy with aspirin and clopidogrel after the first 90 days; to not give direct oral anticoagulant drugs (DOACs) for embolic stroke of undetermined source and to consider pioglitazone in people with diabetes or insulin resistance, after careful consideration of potential risks. In addition to the evidence-based recommendations, the majority of working group members supported: out-of-office BP monitoring; use of combination treatment for BP control; consideration of ezetimibe or PCSK9 inhibitors when lipid targets are not achieved; consideration of use of low-dose DOACs in addition to an antiplatelet in selected groups of people with coronary or peripheral artery disease; and aiming for an HbA1c level of <53 mmol/mol (7%) in people with diabetes mellitus. These guidelines aim to standardise long-term pharmacological treatment to reduce the burden of recurrent stroke in Europe.</p>

SCHOLARONE™
Manuscripts

Declarations Document

Declaration of conflicting interests

All authors have completed a declaration of competing interests and details are available in Supplemental Table 1.

Funding

Funding for the development of these guidelines was provided by the European Stroke Organisation, Basel, Switzerland. The authors did not receive financial support for the development, writing and/or publication of this guideline.

Ethical Approval

Ethical approval was not necessary for the work described in this paper.

Informed consent

Not applicable.

Guarantor

The guarantors of the content of this guideline are Prof Jesse Dawson and Prof Alastair Webb, co-chairs of the Module Working Group.

Contributorship

All members of the MWG were responsible for drafting individual PICO questions. JD and AW wrote the first draft of the manuscript. MTR conducted the statistical analyses. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

1
2
3 **Acknowledgements**
4

5 The authors would like to thank Yvonne Brüchert for her guidance and organisation
6
7 throughout writing of the guideline, Anna Noel-Storr and Josh Cheyne for their advice on
8
9 refining our search strategy.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

ESO secondary prevention guideline supplement

Search strategy employed

Blood pressure related PICO questions

1. exp Stroke/
2. exp Cerebrovascular accident/
3. exp Brain infarction/
4. (stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").ti,ab.
5. ((cerebro* or brain or brainstem or cerebral*) adj3 (infarct* or accident*)).ti,ab.
6. "brain attack*".ti,ab.
7. exp Intracerebral hemorrhage/
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. letter.pt.
10. Letter/
11. editorial.pt.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
12. note.pt.
13. Case report/
14. Case study/
15. exp Animal/ not Human/
16. Nonhuman/
17. exp Animal Studies/
18. Animals, Laboratory/
19. exp Experimental animal/
20. exp Animal experiment/
21. exp Animal model/
22. exp Rodentia/
23. conference abstract.pt.
24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 8 not 24
26. *hypertension/
27. exp hypertension/

For Peer Review

- 1
- 2
- 3 28. exp Antihypertensive Agents/
- 4
- 5 29. exp DIURETICS/
- 6
- 7 30. exp Ganglionic Blockers/
- 8
- 9 31. exp Adrenergic Antagonists/
- 10
- 11 32. exp Calcium Channel Blockers/
- 12
- 13 33. exp Vasodilator Agents/
- 14
- 15 34. exp ADRENERGIC BETA-ANTAGONISTS/
- 16
- 17 35. exp ADRENERGIC ALPHA-ANTAGONISTS/
- 18
- 19 36. exp DIURETICS, THIAZIDE/
- 20
- 21 37. angiotensin II receptor antagonist\$.tw.
- 22
- 23 38. exp LOSARTAN/
- 24
- 25 39. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
- 26
- 27 40. 25 and 39
- 28
- 29 41. randomized controlled trial.pt.
- 30
- 31 42. controlled clinical trial.pt.
- 32
- 33 43. randomized.ab.
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

- 1
- 2
- 3 44. placebo.ab.
- 4
- 5 45. clinical trials as topic.sh.
- 6
- 7
- 8 46. randomly.ab.
- 9
- 10 47. trial.ti.
- 11
- 12 48. 41 or 42 or 43 or 44 or 45 or 46 or 47
- 13
- 14 49. 40 and 48
- 15
- 16
- 17
- 18

19 **Lipid lowering related PICO questions**

- 20
- 21 1. exp Stroke/
- 22
- 23 2. exp Cerebrovascular accident/
- 24
- 25 3. exp Brain infarction/
- 26
- 27 4. (stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").ti,ab.
- 28
- 29 5. ((cerebro* or brain or brainstem or cerebral*) adj3 (infarct* or accident*)).ti,ab.
- 30
- 31 6. "brain attack*".ti,ab.
- 32
- 33 7. exp Intracerebral hemorrhage/
- 34
- 35 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

- 1
- 2
- 3
- 4 9. letter.pt.
- 5
- 6 10. Letter/
- 7
- 8 11. editorial.pt.
- 9
- 10 12. note.pt.
- 11
- 12 13. Case report/
- 13
- 14 14. Case study/
- 15
- 16 15. exp Animal/ not Human/
- 17
- 18 16. Nonhuman/
- 19
- 20 17. exp Animal Studies/
- 21
- 22 18. Animals, Laboratory/
- 23
- 24 19. exp Experimental animal/
- 25
- 26 20. exp Animal experiment/
- 27
- 28 21. exp Animal model/
- 29
- 30 22. exp Rodentia/
- 31
- 32 23. conference abstract.pt.
- 33
- 34 24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

For Peer Review

- 1
- 2
- 3 25. 8 not 24
- 4
- 5 26. exp hyperlipidemia/
- 6
- 7 27. exp antilipemic agents/
- 8
- 9
- 10 28. hypercholesterol\$.tw.
- 11
- 12 29. hyperlipid\$.tw.
- 13
- 14 30. statin\$.tw.
- 15
- 16 31. antilipid\$.tw.
- 17
- 18 32. hyperlip?emia.tw.
- 19
- 20 33. dyslip?emia.tw.
- 21
- 22 34. lipid lowering.tw.
- 23
- 24 35. HMGCoA reductase inhibitor.mp.
- 25
- 26 36. Ezetimibe/ or ezetimibe.mp.
- 27
- 28 37. PCSK9 inhibitor.mp.
- 29
- 30
- 31 38. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
- 32
- 33 39. 25 and 38
- 34
- 35
- 36 40. randomized controlled trial.pt.
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

For Peer Review

- 1
- 2
- 3
- 4 41. controlled clinical trial.pt.
- 5
- 6 42. randomized.ab.
- 7
- 8 43. placebo.ab.
- 9
- 10 44. clinical trials as topic.sh.
- 11
- 12 45. randomly.ab.
- 13
- 14 46. trial.ti.
- 15
- 16
- 17 47. 40 or 41 or 42 or 43 or 44 or 45 or 46
- 18
- 19 48. 39 and 47
- 20
- 21
- 22
- 23

24 **Antithrombotic related related PICO questions**

- 25
- 26 1. exp Stroke/
- 27
- 28 2. exp Cerebrovascular accident/
- 29
- 30 3. exp Brain infarction/
- 31
- 32
- 33 4. (stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").ti,ab.
- 34
- 35 5. ((cerebro* or brain or brainstem or cerebral*) adj3 (infarct* or accident*)).ti,ab.
- 36
- 37 6. "brain attack*".ti,ab.
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

- 1
- 2
- 3 7. exp Intracerebral hemorrhage/
- 4
- 5 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 6
- 7
- 8 9. letter.pt.
- 9
- 10 10. Letter/
- 11
- 12 11. editorial.pt.
- 13
- 14 12. note.pt.
- 15
- 16 13. Case report/
- 17
- 18 14. Case study/
- 19
- 20 15. exp Animal/ not Human/
- 21
- 22 16. Nonhuman/
- 23
- 24 17. exp Animal Studies/
- 25
- 26 18. Animals, Laboratory/
- 27
- 28 19. exp Experimental animal/
- 29
- 30 20. exp Animal experiment/
- 31
- 32 21. exp Animal model/
- 33
- 34 22. exp Rodentia/
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

For Peer Review

- 1
2
3 23. conference abstract.pt.
4
5 24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
6
7 25. 8 not 24
8
9 26. randomized controlled trial.pt.
10
11 27. controlled clinical trial.pt.
12
13 28. randomized.ab.
14
15 29. placebo.ab.
16
17 30. clinical trials as topic.sh.
18
19 31. randomly.ab.
20
21 32. trial.ti.
22
23 33. 26 or 27 or 28 or 29 or 30 or 31 or 32
24
25 34. 25 and 33
26
27 35. exp antithrombocytic agent/
28
29 36. (antiplatelet\$ or anti-platelet\$ or antiaggreg\$ or anti-aggreg\$ or (platelet\$ adj5 inhibit\$) or (thrombocyt\$ adj5 inhibit\$)).tw.
30
31 37. (alprostadi\$ or aspirin\$ or dipyridamol\$ or disintegrin\$ or epoprostenol\$ or iloprost\$ or ketanserin\$ or ketorolac tromethamine\$ or
32
33 milrinone\$ or mopidamol\$ or pentoxifyllin\$ or ticlopidine\$ or thiophen\$ or trapidil\$ or prasugrel or terutroban).tw,tn.
34
35
36
37
38
39
40
41
42
43
44
45
46

- 1
2
3 38. (acetyl salicylic acid\$ or acetyl?salicylic acid or clopidogrel\$ or picotamide\$ or ligustrazine\$ or levamisol\$ or suloctidil\$ or ozagrel\$ or
4
5 oky046 or oky-046 or defibrotide\$ or cilostazol or satigrel or sarpolgrelate or kbt3022 or kbt-3022 or isbogrel or cv4151 or cv-4151 or
6
7 triflusal).tw,tn.
8
9
10 39. (Dispril or Albyl\$ or Ticlid\$ or Persantin\$ or Plavix or Aggrenox or Pletal).tw,tn.
11
12 40. exp fibrinogen receptor/
13
14 41. (((glycoprotein iib\$ or gp iib\$) adj5 (antagonist\$ or inhibitor\$)) or GR144053 or GR-144053 or abciximab\$ or tirofiban\$ or
15
16 eftifibatid\$).tw.
17
18
19 42. (ReoPro or Integrilin\$ or Aggrastat).tw,tn.
20
21 43. exp thrombocyte activation/
22
23 44. exp thrombocyte/
24
25 45. (sulphinpyrazone or sulfinpyrazone or indobufen).tw.
26
27 46. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45
28
29 47. 34 and 46
30
31
32
33
34

Diabetes related PICO questions

- 35
36
37 1. exp Stroke/
38
39
40
41
42
43
44
45
46

- 1
- 2
- 3
- 4 2. exp Cerebrovascular accident/
- 5
- 6 3. exp Brain infarction/
- 7
- 8 4. (stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").ti,ab.
- 9
- 10 5. ((cerebro* or brain or brainstem or cerebral*) adj3 (infarct* or accident*)).ti,ab.
- 11
- 12 6. "brain attack*".ti,ab.
- 13
- 14 7. exp Intracerebral hemorrhage/
- 15
- 16 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 17
- 18 9. letter.pt.
- 19
- 20 10. Letter/
- 21
- 22 11. editorial.pt.
- 23
- 24 12. note.pt.
- 25
- 26 13. Case report/
- 27
- 28 14. Case study/
- 29
- 30 15. exp Animal/ not Human/
- 31
- 32 16. Nonhuman/
- 33
- 34 17. exp Animal Studies/
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

- 1
- 2
- 3 18. Animals, Laboratory/
- 4
- 5 19. exp Experimental animal/
- 6
- 7 20. exp Animal experiment/
- 8
- 9
- 10 21. exp Animal model/
- 11
- 12 22. exp Rodentia/
- 13
- 14 23. conference abstract.pt.
- 15
- 16
- 17 24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
- 18
- 19 25. 8 not 24
- 20
- 21 26. randomized controlled trial.pt.
- 22
- 23 27. controlled clinical trial.pt.
- 24
- 25 28. randomized.ab.
- 26
- 27 29. placebo.ab.
- 28
- 29 30. clinical trials as topic.sh.
- 30
- 31 31. randomly.ab.
- 32
- 33 32. trial.ti.
- 34
- 35 33. 26 or 27 or 28 or 29 or 30 or 31 or 32
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

- 1
- 2
- 3 34. 25 and 33
- 4
- 5 35. diabet\$.tw,ab.
- 6
- 7 36. diabetes mellitus/
- 8
- 9
- 10 37. non insulin dependent diabetes mellitus/
- 11
- 12 38. insulin resistance/
- 13
- 14 39. glucose intolerance.tw,ab.
- 15
- 16 40. impaired glucose tolerance.tw,ab.
- 17
- 18 41. insulin resistance.tw,ab.
- 19
- 20 42. mody.tw,ab.
- 21
- 22 43. dm2.tw,ab.
- 23
- 24 44. niddm.tw,ab.
- 25
- 26 45. iddm.tw,ab.
- 27
- 28 46. non insulin dependent.tw,ab.
- 29
- 30 47. noninsulin dependent.tw,ab.
- 31
- 32 48. noninsulindependent.tw,ab.
- 33
- 34 49. ((typ\$ 2 or typ\$ II or typ\$ 1 or typ\$ I) adj3 diabet\$.ti,ab.
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

For Peer Review

- 1
- 2
- 3 50. metabolic syndrom*.tw,ab.
- 4
- 5 51. plurimetabolic syndrom*.ti,ab.
- 6
- 7
- 8 52. pioglitazone.tw,ab.
- 9
- 10 53. HbA1c.tw,ab.
- 11
- 12 54. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53
- 13
- 14
- 15 55. 34 and 54
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

For Peer Review

Disclosures / Conflicts of interest**Supplementary Table 1. Intellectual and financial disclosures of the module working group members**1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Module working group member	Discipline and affiliation	Intellectual and financial disclosures
Yannick Béjot	Neurology University Hospital of Dijon, France	Intellectual disclosures: Associate Editor “Frontiers in Neurology” Assistant Editor “Stroke” Financial disclosures Lecture fees: BMS Pfizer, Medtronic, Amgen, Servier, and Boehringer-Ingelheim Consultant fees: NovoNordisk, Medtronic
Jesse Dawson	Stroke Medicine, University of Glasgow	Intellectual disclosures: Research funding from Pfizer and BMS for research projects concerning detectio of atrial fibrillation after stroke. Financial disclosures

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		Speaker fees: BMS, Pfizer, Medtronic, Boehringer-Ingelheim, Daicchi Sanyko, Astra-Zeneca, Bayer
Linxin Li	Neurology University of Oxford	Intellectual disclosures: Associate Editor “Frontiers in Neurology” Financial disclosures Funded by Medical Research Foundation
Guri Hagberg	Geriatrics and internal medicine Oslo University Hospital	Intellectual disclosures: - Financial disclosures Lecture fees: Boehringer-Ingelheim, BMS Pfizer, Bayer AG
Alastair Webb	Neurology University of Oxford	Intellectual disclosures: Associate Editor “Frontiers in Neurology” Financial disclosures Funded by a Wellcome Trust Clinical Research Career Development Fellowship

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<p>Francesca Romana Pezzella</p>	<p>Stroke Unit, Department of Neuroscience, San Camillo Forlanini Hospital. Rome, Italy</p>	<p>Intellectual disclosures: CO- Chair, The Stroke Action Plan Implementation Steering Committee Secretary General: ISA-AII Italian Stroke Association - Associazione Italiana Ictus</p> <p>Financial disclosures Stroke Consultant: Italian National Agency for Regional Healthcare Services (AGENAS)</p>
<p>Cristina Tiu</p>	<p>Neurology University of medicine and Pharmacy “Carol Davila” Bucharest, Romania</p>	<p>Intellectual disclosures: -</p> <p>Financial disclosures Lecture fees: Boehringer-Ingelheim, Merck, Biogen, Novartis, Roche</p>
<p>Haralampos Milionis</p>	<p>Internal Medicine University of Ioannina, Greece</p>	<p>Intellectual disclosures: Associate Editor “Journal of Atherosclerosis Prevention and Treatment”</p> <p>Financial disclosures Lecture and Consultant fees: Amgen, Bayer, Pfizer, Viatris</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Martin Dichgans	<p>1) Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany;</p> <p>2) Munich Cluster for Systems Neurology (SyNergy), Munich, Germany</p>	<p>Intellectual disclosures: President of ESO</p> <p>Financial disclosures -</p>
Louisa M. Christensen	<p>Department of Neurology, Copenhagen University Hospital Bispebjerg & Copenhagen University, Faculty of Health and Medical Sciences</p>	<p>Intellectual disclosures: Member of Board of Directors ESO</p> <p>Financial disclosures none</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<p>Gian Marco De Marchis</p>	<p>Department of Neurology & Stroke Center, University Hospital Basel & University of Basel</p>	<p>Intellectual disclosures:</p> <p>Editor “Stroke” and “European Stroke Journal”.</p> <p>Member of the Guideline Board of the European Stroke Organisation.</p> <p>Financial disclosures</p> <p>Funded by the Swiss National Science Foundation, travel honoraria by Bayer and BMS/Pfizer; speaker honoraria by Bayer and Medtronic; consultant honoraria by Bayer and Novartis. He is member of the Steering Committee of PACIFIC Stroke (NCT04304508). Industry payments are made to the research fund of the University Hospital Basel.</p>
<p>Mirjam Heldner</p>	<p>Stroke Research Center Bern, Department of Neurology, University and University hospital Bern, Bern, Switzerland</p>	<p>Intellectual disclosures</p> <p>Associate Editor Frontiers in Neurology and Editorial Board Member and Review Editor for BMC Neurology/Stroke</p> <p>Financial disclosures</p> <p>Travel support from Bayer, personal fees for advisory board participation from Amgen</p>

Supplementary table 2.

Results of voting for the expert consensus statements.

PICO Question and statement	MWG	MWG	MWG	MWG	MWG	MWG	MWG	MWG	MWG	MWG	MWG	MWG
	1	2	3	4	5	6	7	8	9	10	11	12
PICO Q2: In people with a history of TIA or ischaemic stroke starting antihypertensive therapy, does use of out of office blood pressure measurements compared to outpatient clinic measurements provide better long-term control of blood pressure?												
In people with previous ischaemic stroke or TIA, we support the use of out of office blood pressure measurements wherever feasible, to achieve better long-term control of blood pressure.	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
PICO Q4: In people with a history of TIA or ischaemic stroke starting antihypertensive therapy, does initiation of 2 blood pressure lowering medications compared to monotherapy reduce the risk of recurrent stroke?												
In people with previous TIA or stroke, we support initiation of a combination of two blood pressure lowering drugs to reduce the risk of	YES	NO	YES	YES	YES	YES	YES	NO	YES	YES	YES	YES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<p>recurrent stroke, with consideration of monotherapy where there are potential risks of hypotension, such as in frail, elderly people and people with borderline hypertension.</p>												
<p>PICO Q7: In people with TIA or ischaemic stroke who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a statin for at least 6 weeks, is the addition of ezetimibe and/or PCSK9-inhibitor superior to statin alone to reduce the risk of recurrent stroke?</p>												
<p>In people with ischaemic stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, we support the addition of Ezetimibe as an option to reduce the risk of recurrent major cardiovascular events. The use of a PCSK9 inhibitor may be considered in some people with difficult to attain low LDL-C targets.</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>	<p>YES</p>

PICO Q10: In people with TIA or ischaemic stroke and atherosclerosis, with no other indication for anticoagulation, does antiplatelet therapy combined with a low-dose direct oral anticoagulant compared to antiplatelet therapy alone reduce the risk of recurrent stroke?

The use of antiplatelet therapy combined with a low-dose direct oral anticoagulant (rivaroxaban) can be considered to optimise treatment of coronary artery disease or peripheral arterial disease in people with a history of ischaemic stroke or TIA more than one month.

YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

PICO Q12: In people with diabetes mellitus and ischaemic stroke or TIA, does intensive control of glycated haemoglobin level (HbA1c) compared to less intensive HbA1c control reduce the risk of recurrent stroke?


In people with ischaemic stroke or TIA and diabetes mellitus, we support aiming for an HbA1c level of <53mmol/mol (7%) to reduce risk of microvascular and macrovascular complications, however, this target may need to

YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

be individualised based on duration of diabetes, age and comorbidities.													
--	--	--	--	--	--	--	--	--	--	--	--	--	--


Supplementary figure 1. Results for outcome of any stroke for PICO question 5 when only trials starting therapy early after stroke were included.



Meta Analysis

Forest plot for the risk of any stroke in trials comparing treatment with HMGCoA reductase inhibitors versus placebo after TIA or stroke, recruited early after their stroke for outcome of any stroke. Heterogeneity: I-squared =0.000; Q-value=0.372

Supplementary figure 3. Results for outcome of haemorrhagic stroke for PICO question 9 by type of dual antiplatelet therapy.



Meta Analysis

Forest plot for the risk of haemorrhagic stroke in trials comparing treatment with dual vs. antiplatelet monotherapy after ischaemic stroke or TIA. Heterogeneity: Aspirin and Clopidogrel I-squared= 0.000, q=0.398, p=0.528. Aspirin and Dipyridamole I-squared= 0.000, q=0.00, p=1.

European Stroke Organisation (ESO) Guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack

Jesse Dawson

Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 9QQ, UK.

ORCID: 0000-0001-7532-2475

Yannick Béjot

Dijon Stroke Registry, Department of Neurology, University Hospital of Dijon, EA7460, Pathophysiology and Epidemiology of Cardio-cerebrovascular disease (PEC2), University of Burgundy, France.

ORCID: 0000-0001-7848-7072

Louisa M. Christensen

Copenhagen University Hospital Bispebjerg, Dept of Neurology, Denmark.

ORCID: 0000-0003-1448-5646

Gian Marco De Marchis

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Switzerland.

ORCID: 0000-0002-0342-9780

Martin Dichgans^{1,2}

¹ Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany; ² Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

ORCID: 0000-0002-0654-387X

Guri Hagberg

1
2
3 Oslo Stroke Unit, Department of Neurology, Oslo University Hospital, Ullevål, Norway,
4
5 Department of medical research, Bærum Hospital Vestre Viken Hospital Trust, Drammen,
6
7 Norway.
8
9

10 ORCID: 0000-0003-2822-7701
11

12 Mirjam R Heldner, Stroke Research Center Bern, Department of Neurology, University and
13
14 University hospital Bern, Bern, Switzerland
15

16 ORCID 0000-0002-3594-2159
17
18

19 Haralampos Milionis
20

21 Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University
22
23 of Ioannina, Ioannina, Greece.
24
25

26 ORCID: 0000-0003-3958-2266
27
28

29 Linxin Li
30

31 Wolfson Centre for Prevention of Stroke and Dementia, Department of Clinical
32
33 Neurosciences, University of Oxford, Oxford, OX3 9DU.
34

35 ORCID: 0000-0002-3636-8355
36
37

38 Francesca Romana Pezzella, MD, PhD, BSc, FESO
39

40 Stroke Unit, Department of Neuroscience, San Camillo Forlanini Hospital, Rome 00153,
41
42 Italy.
43

44 ORCID: 0000-0002-5902-2795
45
46

47 Martin Taylor Rowan
48

49 Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life
50
51 Sciences, University of Glasgow, Glasgow, G12 9QQ, UK.
52

53 ORCID ID: 0000-0002-0654-387X
54
55

56 Cristina Tiu
57
58
59
60

1
2
3 University of Medicine and Pharmacy “Carol Davila”, Department of Clinical
4
5 Neurosciences, University Hospital Bucharest, Department of Neurology, Romania.
6

7
8 ORCID: 0000-0001-8532-6218
9

10 Alastair Webb

11
12 Wolfson Centre for Prevention of Stroke and Dementia, Department of Clinical
13
14 Neurosciences, University of Oxford, Oxford, OX3 9DU

15
16
17 ORCID: 0000-0002-0630-8204
18
19

20
21
22 Correspondence to:

23
24 Prof Jesse Dawson

25
26 Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life
27
28 Sciences, University of Glasgow, Glasgow, G12 9QQ, UK.
29

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Abstract

Recurrent stroke affects 9-15% of people after 1 year. This European Stroke Organisation (ESO) guideline provides evidence-based recommendations on pharmacological management of blood pressure (BP), diabetes mellitus, lipid levels and antiplatelet therapy for the prevention of recurrent stroke and other important outcomes in people with ischaemic stroke or transient ischaemic attack (TIA). It does not cover interventions for specific causes of stroke, including anticoagulation for cardioembolic stroke, which are addressed in other guidelines. This guideline was developed through ESO standard operating procedures and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology. The working group identified clinical questions, selected outcomes, performed systematic reviews, with meta-analyses where appropriate, and made evidence-based recommendations, with expert consensus statements where evidence was insufficient to support a recommendation.

To reduce the long-term risk of recurrent stroke or other important outcomes after ischaemic stroke or TIA, we recommend: BP lowering treatment to a target of <130/80 mmHg, except in subgroups at increased risk of harm; HMGCoA-reductase inhibitors (statins) and targeting a low density lipoprotein level of <1.8 mmol/l (70 mg/dl); avoidance of dual antiplatelet therapy with aspirin and clopidogrel after the first 90 days; to not give direct oral anticoagulant drugs (DOACs) for embolic stroke of undetermined source and to consider pioglitazone in people with diabetes or insulin resistance, after careful consideration of potential risks. In addition to the evidence-based recommendations, the majority of working group members supported: out-of-office BP monitoring; use of combination treatment for BP control; consideration of ezetimibe or PCSK9 inhibitors when lipid targets are not achieved; consideration of use of low-dose DOACs in addition to an antiplatelet in selected groups of

1
2
3 people with coronary or peripheral artery disease; and aiming for an HbA1c level of <53
4
5 mmol/mol (7%) in people with diabetes mellitus.
6

7
8 These guidelines aim to standardise long-term pharmacological treatment to reduce the
9
10 burden of recurrent stroke in Europe.
11

12
13
14 Keywords: guideline, systematic review, stroke, hypertension, dyslipidaemia, diabetes,
15
16 antiplatelet
17

18
19
20
21 The full version of this guideline appears online.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Approximately 1.1 million people in Europe suffer a stroke each year (1). The majority of these are ischaemic, with approximately half as many people again experiencing a transient ischaemic attack (TIA) (2). People with a history of ischaemic stroke or TIA are at an increased risk of recurrent stroke and cardiovascular events, including myocardial infarction.

Following ischaemic stroke, the rate of any recurrent stroke has been reported to range between 9% and 15% after 1 year, dependent on stroke aetiology (3). The rate of recurrent stroke at 10 years is reported as being between 27% and 40%. People with large artery disease have a reported rate of acute coronary syndrome of 22% over 10 years. In a recently reported international cohort study, 6% of people with TIA suffered a stroke within 1-year and 12% suffered a stroke or TIA (4).

Several advances have recently been made in pharmacological preventative strategies for first and recurrent stroke. These include new drug classes for antithrombotic and lipid lowering therapy and for treatment of diabetes mellitus. In addition, several studies have assessed treatment targets for cholesterol and blood pressure (BP) level and compared investigative strategies to detect modifiable causes such as atrial fibrillation. Most cases of stroke can be explained by known cerebrovascular risk factors, with over 80% of the population attributable risk being explained by hypertension, smoking, diet, diabetes, alcohol use, psychological factors, activity levels and cardiac causes (5). There is therefore extensive opportunity to prevent recurrent stroke in people with stroke and TIA through readily available treatments. However, this can be hard to achieve in practice with several studies reporting sub-optimal risk factor control (6).

The European Stroke Organisation (ESO) prepared a European Stroke Action Plan in 2018 which set targets to reduce the number of strokes in Europe by 10% (7). Effective secondary

1
2
3 prevention measures, that are implementable on a wide scale, are key to this aim. The aim of
4
5 this guideline is to provide recommendations to physicians treating people with ischaemic
6
7 stroke or TIA to help them reach decisions regarding antithrombotic, BP lowering and lipid
8
9 lowering treatment and regarding blood glucose control for prevention of recurrent stroke.
10
11 The use of short term dual anti-platelet therapy early after minor stroke and high-risk TIA
12
13 (8), secondary prevention in people with atrial fibrillation (9) or haemorrhagic stroke (10),
14
15 and acute management after stroke or TIA (11) are covered in previously guidelines. The use
16
17 of lifestyle measures to prevent stroke will be discussed in future guidelines.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Methods

Composition and approval of the Module Working Group

These guidelines were initiated by the ESO. Two chairpersons (JD and AW) were selected to assemble and coordinate the Guideline Module Working Group (MWG). The final group contained 13 experts. The ESO Guideline Board and Executive Committee reviewed the intellectual and financial disclosures of all MWG members and approved the composition of the group. The full details of all MWG members and their disclosures is included in Supplemental Materials.

Development and approval of clinical questions

The guidelines were developed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology (12) and the ESO Standard Operating Procedure (SOP) (13), as described previously. In brief, the MWG developed a list of topics, and corresponding outcomes of clinical interest, within 4 key topic areas: 1) BP management; 2) lipid-lowering therapy; 3) antithrombotic therapy and; 4) management of diabetes mellitus. The topics and outcomes were independently rated by each group member as critical, important or of limited importance according to GRADE criteria. The list of outcomes and results of voting are given in table 1. Critical outcomes were defined as having either a mean or median score of 7 or more. Once critical outcomes had been identified, we established whether they were critical for all 4 key topic areas. Any stroke, ischaemic stroke, and major cardiovascular events were viewed as critical for all 4 topic areas. Bleeding outcomes were agreed as critical for lipid lowering and antithrombotic PICO questions. To avoid duplication, we included haemorrhagic stroke as a critical outcome but not intracranial bleeding. Functional outcome was initially rated as critical, but it was agreed that this would be downgraded to important and not be used to influence summary GRADE certainty assessment as there would be little data on this outcome in secondary prevention trials.

1
2
3 Dementia was rated as important and was included as an outcome for the PICO questions as
4
5 we agreed readers would be interested in this outcome if data were available. However, it was
6
7 not used to influence summary of GRADE certainty. In addition, we defined in advance that
8
9 the outcome for PICO question 2 was blood pressure level. For our overall assessment of
10
11 quality of evidence for each PICO question we used the lowest level of evidence for a critical
12
13 outcome unless otherwise stated.
14
15

16
17 A series of PICO questions were then developed and approved by the ESO Guideline Board
18
19 and the ESO Executive Committee.
20
21

22 **Literature search**

23
24 Search terms were developed by the MWG and guideline methodologist. Where a validated
25
26 search strategy was available, this was used or adapted. A single broad search was performed
27
28 for each topic area. Identified titles were then reviewed separately for each PICO question.
29

30
31 Where there was a recent relevant systematic review on the question of interest, the
32
33 corresponding search strategy and results were used and updated as necessary. Search
34
35 strategies are described in the Supplementary Materials. MTR, JD and AW agreed on the
36
37 search terms for each PICO question.
38
39

40
41 The search was performed by the ESO Guideline methodologist (MTR). The following
42
43 databases were searched: the Cochrane Library, Embase and Medline from inception to 9th
44
45 April 2021. Search results were run through the Cochrane machine learning randomised
46
47 controlled trial classifier, to restrict results to randomised controlled trials only (14). Reference
48
49 lists of review articles, the authors' personal reference libraries, and previous guidelines were
50
51 also searched for additional relevant records.
52
53

54
55 Search results were loaded into the web-based Covidence platform (Health Innovation,
56
57 Melbourne, Australia) for assessment by the MWG. Two or more MWG members were
58
59 assigned to independently screen the titles and abstracts of publications registered in Covidence
60

1
2
3 and then assess the full text of studies determined to be potentially relevant. All disagreements
4
5 were resolved by discussion between the two reviewers or by a third MWG member.
6

7
8 We excluded publications with only conference abstracts available. For a study to be
9
10 considered eligible, all of the following criteria needed to be met: report of data from a
11
12 randomised controlled trial; performed only in adults (≥ 18 years) with ischaemic stroke or
13
14 TIA (or reported outcomes separately for this group); inclusion of at least 50 participants per
15
16 treatment group; at least three months follow up; and assessment of an intervention specified
17
18 by one of the included PICO questions. As PICO 2 assessed the efficacy of outpatient blood
19
20 pressure monitoring, it included studies with a primary outcome of blood pressure control at 3
21
22 months or more.
23
24

25 26 **Data analysis**

27
28 Data extraction and analysis was performed by the ESO methodologist. In the case that relevant
29
30 data were not reported in an eligible study, the corresponding author was contacted. In case of
31
32 no response, the co-authors of the study were also contacted. If no answer was received, data
33
34 were considered as missing.
35
36

37
38 Where appropriate, fixed or random-effects meta-analyses were conducted using Review
39
40 Manager (RevMan) software (Cochrane). Results were presented as estimates of effect with
41
42 associated 95% confidence intervals (95% CIs). Statistical heterogeneity across studies was
43
44 assessed using the I-squared statistic, and classified as moderate ($\geq 30\%$), substantial ($\geq 50\%$),
45
46 or considerable ($\geq 75\%$).⁽¹⁵⁾
47
48

49 **Evaluation of the quality of evidence and formulation of recommendations**

50
51 The risk of bias of each included randomised trial was assessed with the Cochrane Rob2 tool
52
53 (16). As recommended, the evidence synthesis did not use a quality 'score' threshold but
54
55 classified overall risk of bias at study level and then in aggregate (17).
56
57
58
59
60

1
2
3 The results of data analysis were imported into the GRADEpro Guideline Development Tool
4 (McMaster University, 2015; developed by Evidence Prime, Inc.) For each PICO question, and
5
6 each outcome, the following were considered: risk of bias based on the type of available
7
8 evidence (randomised or observational studies); inconsistency of results; indirectness of
9
10 evidence, imprecision of results, and other possible bias. GRADE evidence profiles/summary
11
12 of findings tables were generated and used to prepare recommendations. “Evidence-based
13
14 Recommendations” were based on the GRADE methodology. The direction, strength and
15
16 formulation of the recommendations were determined according to the GRADE evidence
17
18 profiles and the ESO-SOP (12, 13, 18).
19
20
21
22

23
24 Finally, Expert Consensus Statements were added whenever the MWG considered that there
25
26 was insufficient evidence available to provide Evidence-based Recommendations and where
27
28 practical guidance is needed for routine clinical practice. The Expert Consensus Statements
29
30 were based on voting by all expert MWG members. Importantly, these Expert Consensus
31
32 Statements should not be regarded as Evidence-based Recommendations, since they only
33
34 reflect the opinion of the writing group.
35
36
37
38
39

40 **Drafting of the document, revision and approval**

41
42 Each PICO question was addressed in distinct sections, in line with the updated ESO SOP
43
44 (13). First, “Analysis of current evidence” summarised current pathophysiological
45
46 considerations followed by a summary and discussion of the results of the identified RCTs
47
48 and other studies. Second, “Additional information” was added when more details on the
49
50 studies referred to in the first section were needed to provide information on key subgroup
51
52 analyses of the included studies, on ongoing or future RCTs, and on other studies which can
53
54 provide important clinical guidance on the topic.
55
56
57
58
59
60

1
2
3 Third, an ‘Expert Consensus Statement’ paragraph was added whenever the MWG
4
5 considered that insufficient evidence was available to provide evidence-based
6
7 recommendations for situations in which practical guidance is needed for everyday clinical
8
9 practice.

10
11
12 The Guideline document was reviewed several times by all MWG members and modified
13
14 using a Delphi approach until consensus was reached. The final submitted document was
15
16 peer-reviewed by two external reviewers, two members of the ESO Guideline Board and one
17
18 member of the Executive Committee.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Results

Blood pressure lowering

PICO question 1: In people with a history of ischaemic stroke or TIA, does blood pressure lowering treatment compared to no blood pressure lowering treatment reduce the risk of any recurrent stroke?

Analysis of current evidence

Hypertension is the most prevalent risk factor for stroke. BP level has a log-linear relationship with risk of stroke. A 20 mmHg systolic or 10 mmHg diastolic increase in BP is associated with an approximate doubling of the risk of stroke (19). Elevated BP after ischaemic stroke or TIA is also a risk factor for recurrence (19, 20).

Our systematic review and search of associated reference lists identified 5482 titles, of which 281 were reviewed in full. Ten trials of antihypertensive drugs versus placebo after TIA or stroke were eligible (21-30), including reports of secondary prevention subgroups in larger trials of mixed populations. The shortest reported period from stroke to randomisation was a median of 15 days (23) with most trials enrolling people months after stroke.

Results for all considered outcomes and GRADE scoring are available in Table 2. On meta-analysis of data from 9 trials (21-29), with a median duration of follow-up ranging from 2 to 4.5 years, there was a significant reduction in the odds of recurrent stroke by almost 20% (OR 0.81, 95% CI 0.71-0.92, $p=0.002$) with BP lowering treatment (figure 1, table 2). The use of BP lowering treatment would be expected to lead to 17 fewer strokes per 1000 people treated. There was substantial heterogeneity ($I^2=53$, $p=0.03$), giving only moderate certainty, largely due to the largest trial with one of the smallest achieved BP differences between groups (the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS)). An exploratory analysis removing PROFESS (23) resulted in a 25% reduction in stroke risk (OR 0.75, 95% CI 0.68-0.83) with no residual heterogeneity ($I^2=0$).




Figure 1. Forest plot for the risk of any stroke in randomised trials of antihypertensive medication versus placebo after stroke or TIA. Heterogeneity; I-squared=53, p=0.03.

On meta-analysis of data from 3 trials (22, 23, 30) there was a non-significant reduction in ischaemic stroke (OR 0.85, 95% CI 0.68-1.050, p=0.13). On meta-analysis of data from 2 trials (22, 23) there was a non-significant reduction in haemorrhagic stroke (OR 0.66, 0.38-1.13, p=0.13) but certainty was rated as very low due to a small number of events. There was a significant reduction in major cardiovascular events (7 trials (22-28), OR 0.80, 95% CI 0.69 to 0.94, p=0.006, I-squared=72.5, figure 2, table 2) and cardiovascular death (6 trials (21, 23-25, 27, 28), OR 0.88, 95% CI 0.78-0.99, p=0.026, I-squared=0) with antihypertensive therapy (table 2). There was no significant reduction in myocardial infarction (6 trials (21, 23-25, 27, 28), OR 0.85, 95% CI 0.69 to 1.04, p=0.11) and all cause death (7 trials (21, 23-25, 27, 28), OR 0.97, 95% CI 0.90 to 1.05, p=0.51, I-squared=0). There were insufficient data to allow

analysis of the effect of antihypertensive medication on dementia and functional outcome and there were no significant differences seen for these outcomes in any individual trial we reviewed (table 2).




Figure 2. Forest plot for the risk of recurrent major adverse cardiovascular events in randomised trials of antihypertensive medication versus placebo after stroke or TIA. Heterogeneity: I-squared=72.506; Q=21.823; p=0.001

There was no important concern of significant bias in the results, but there was substantial heterogeneity between studies for the outcomes of any stroke and major cardiovascular events. This led to a rating of only moderate certainty for these outcomes. However, as described above, this heterogeneity predominantly resulted from inclusion of PROFESS (23) which produced a more conservative estimate of the effect size. Exclusion of the PROFESS trial data from the analyses resulted in a greater difference between the intervention and control groups and removed our concerns regarding inconsistency. Therefore, taking this into account and because the level of certainty was high for cardiovascular death, we rated the

1
2
3 overall quality of evidence as high for this PICO question. Achieved BP differences were
4
5 variable between studies, ranging from 3.2/2.0 mmHg in PROFESS to 25.0/12.0 mmHg in
6
7 HSCS.
8
9

10 **Additional information**

11
12 The conclusions of our meta-analyses are consistent with those of recent meta-analyses
13
14 performed in 2018 (31) and 2017 (32), based upon a very similar groups of trials. The latter
15
16 of these analyses also supported a linear relationship between degree of BP reduction in these
17
18 studies and achieved differences in outcomes. Furthermore, the effect of BP lowering in our
19
20 meta-analysis is highly consistent with the benefits of BP lowering in primary prevention of
21
22 stroke and other secondary prevention populations. In the largest available individual
23
24 participant-level meta-analysis, there was an approximate 10% reduction in the risk of major
25
26 adverse cardiovascular events for each 5 mmHg reduction in systolic BP in both primary and
27
28 secondary prevention populations. In people with prior cardiovascular disease, there was a
29
30 reduction in all major cardiovascular events by 11% (OR 0.89, 95% CI 0.86 to 0.92) and
31
32 stroke by 11% (OR 0.89, 95% CI 0.85 to 0.94), but no effect for all cause death (33).
33
34
35
36

37 Benefits of BP reduction in individual participant-level meta-analyses in primary prevention
38
39 were consistent regardless of baseline BP level, even down to normotensive levels (120/70
40
41 mmHg). However, confidence in benefits at these lower BP levels is limited due to
42
43 heterogeneity between populations and smaller numbers (33). The benefit of antihypertensive
44
45 treatment in secondary prevention of stroke at mildly hypertensive levels is supported by the
46
47 PROGRESS trial, in which the risk of recurrent stroke was reduced by treatment in both
48
49 hypertensive and non-hypertensive populations, with hypertension defined as BP greater than
50
51 140/90 mmHg.
52
53
54

55 The timing of intervention in the studies included in our meta-analysis varied significantly,
56
57 but treatment was not initiated in the acute phase in any of these trials, and the risk of
58
59
60

1
2
3 recurrent events was consistently reduced during follow-up. As such, our recommendations
4
5 apply for all participants after a cerebrovascular event, but do not provide a specific
6
7 recommendation regarding the timing of initiation of therapy.
8
9
10
11

12 **Evidence-based Recommendation**

13
14 In people with previous ischaemic stroke or TIA, we recommend blood pressure lowering
15
16 treatment to reduce the risk of recurrent stroke.
17
18

19
20
21 Quality of evidence: **High** ⊕⊕⊕⊕

22
23
24 Strength of recommendation: **Strong for intervention** ↑ ↑
25
26
27

28
29
30 **PICO question 2:** In people with a history of ischaemic stroke or TIA starting
31
32 antihypertensive therapy, does use of out-of-office blood pressure measurements compared to
33
34 clinic measurements provide better long-term control of blood pressure?
35

36 **Analysis of current evidence**

37
38 Our systematic review and search of associated reference lists identified 5482 titles, of which
39
40 281 were reviewed in full. For this question we identified three trials comparing out-of-office
41
42 BP measurements versus out-of-office BP measurements in people after stroke or TIA (34-
43
44 36).
45
46

47
48 The Trial of the Effectiveness of Self-monitoring / Treatment of BP after Stroke (TEST-BP)
49
50 trial (36) randomised 171 participants with a recent stroke or TIA to self-BP monitoring with
51
52 or without guided self-management of BP treatment vs. treatment as usual. The primary
53
54 outcome was difference in daytime ambulatory systolic BP (SBP) at six months. There were
55
56 no significant mean between-group differences at six months (difference treatment as usual
57
58 minus self monitoring and management, 2.69 mmHg (95% CI, -2.59 to 7.97; P =0.31);
59
60

1
2
3 treatment as usual minus self monitoring only, 3.00 mmHg (95% CI, -2.53 to 8.54; P =0.28).

4
5 Self-BP monitoring did not result in more participants achieving target BP, defined as
6
7 daytime blood pressure on ambulatory monitoring of $\leq 120/75$ mmHg (treatment as usual
8
9 12/52 (23%), treatment as usual 8/51 (16%), self monitoring and management 13/51 (26%),
10
11 P>0.05).

12
13
14 In the study by Kerry et al. (35), 381 participants with hypertension and a history of stroke or
15
16 TIA were randomised to home BP monitoring or usual care. The primary outcome was a fall
17
18 in systolic BP after 12 months. There was no significant mean between-group difference (0.3
19
20 mmHg, 95% CI, -1.36 to 4.2). Subgroup analysis showed significant interaction with
21
22 disability due to stroke (p = 0.03 at 6 months) and baseline BP (p = 0.03 at 12 months).

23
24 The Targets and Self-Management for the Control of Blood Pressure in Stroke and at Risk
25
26 Groups (TASMIN-SR) Trial (34) randomised 552 participants with a history of stroke or
27
28 TIA, coronary heart disease, diabetes, or chronic kidney disease and baseline BP of at least
29
30 130/80 mmHg to a self-monitoring of BP combined with an individualised self-titration
31
32 algorithm vs. usual care. The primary outcome was the difference in systolic BP between
33
34 intervention and control groups at the 12-month office visit. After 12 months, there was a
35
36 mean systolic BP difference of 9.2 mmHg (95% CI, 5.7 to 12.7) between the groups without
37
38 increasing adverse events. In a prespecified subgroup analysis including 77 participants with
39
40 a history of stroke, there was no significant mean between-group difference (8.9 mmHg, 95%
41
42 CI, -1.1 to -19.1) at 12 months.

43
44
45 On meta-analysis of data from these three trials, there was no significant mean between-
46
47 group difference (-2.34 mmHg, 95% CI, -1.45 to 6.13, p=0.227) in BP (figure 3, table 3).

48
49
50 There was no substantial heterogeneity (I-squared=26, p=0.26) between the trials, and an
51
52 exploratory analysis removing TASMIN-SR (34) resulted in a smaller mean difference (MD
53
54
55
56
57
58
59
60

1
2
3 1.15, 95% CI -1.96 to 4.27) with no residual heterogeneity ($I^2=0$). The level of certainty was
4
5 rated as low due to imprecision.
6

7 **Supporting information to the expert consensus statement**

8
9
10 Our metanalysis did not find significantly better BP control by home monitoring, but
11
12 confidence intervals were wide and heterogeneous groups of participants were included in
13
14 the trials. We conclude that in people with previous ischaemic stroke or TIA, there are
15
16 insufficient data to provide a recommendation for the PICO question. As there was no
17
18 reported harm in the secondary prevention population, a consensus decision was reached
19
20 based partly on previous evidence and guidance for primary prevention. In the TASMIN-SR
21
22 trial (34), self-monitoring of BP combined with an individualised self-titration algorithm
23
24 resulted in a significant reduction in BP at 12 months. As shown in the study from Kerry et
25
26 al.(35), a subgroup analysis revealed significant interaction with disability due to stroke,
27
28 where 30 % required the help of a care provider to take their BP, and age ranged from 30 to
29
30 94 years. Out-of-office monitoring is currently recommended in the 2021 ESC Guidelines on
31
32 cardiovascular disease prevention in clinical practice with self-monitoring of BP when
33
34 feasible (37), as it may have a beneficial effect on medication adherence and BP control (38),
35
36 especially in treated higher-risk people. However, patient selection seems essential to ensure
37
38 the effectiveness of home monitoring. The panel voted by 12 / 12 members for the following
39
40 consensus statement (supplementary table 2).
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Forest plot for the difference in achieved mean blood pressure between ‘treatment as usual’ and introduction of home or remote blood pressure monitoring after stroke or TIA. Heterogeneity: I-squared=0.000; Q=1.509; p=0.470

Evidence-based Recommendation

-

Quality of evidence: -

Strength of recommendation: -

Expert Consensus Statement

In people with previous ischaemic stroke or TIA, we support the use of out of office blood pressure measurements wherever feasible, to achieve better long-term control of blood pressure.

PICO question 3: In people with a history of ischaemic stroke or TIA starting or increasing antihypertensive therapy, does treating to a more intensive (i.e. blood pressure <130/80) versus less intensive (<140/90 mmHg) target reduce the risk of recurrent stroke?

Analysis of current evidence

Our systematic review and search of associated reference lists identified 5482 titles, of which 281 were reviewed in full. For this question we identified three trials in which an intensive BP reduction strategy was compared with a standard BP target and reported risk of recurrent stroke in people with a history of stroke or TIA (39-41). The Secondary Prevention of Small Subcortical Strokes (SPS3) (39) trial included 3020 participants with MRI-confirmed symptomatic lacunar ischaemic stroke within 180 days to compare a SBP target of 130–149 mmHg versus a SBP <130 mmHg. After a mean follow-up of 44 months, the primary endpoint (all strokes) was observed in 125 (2.25%) participants in the intensive SBP target group versus 152 (2.77%) participants in the standard SBP target group (HR 0.81, 95% CI 0.64 to 1.03, $p=0.08$). The intensive SBP reduction strategy was associated with a reduction in haemorrhagic stroke (HR 0.37, 95% CI 0.15 to 0.85, $p=0.03$). No statistically significant difference was observed between groups for other secondary outcomes including ischaemic stroke (HR 0.84, 95% CI 0.66 to 1.09, $p=0.19$), myocardial infarction (HR 0.88, 95% CI 0.56-1.39, $p=0.59$), major vascular events (HR 0.84, 95% CI 0.68 to 1.04, $p=0.1$), all-cause death (HR 1.03, 95% CI 0.79 to 1.35, $p=0.82$), or vascular death (HR 0.86, 95% CI 0.55 to 1.35, $p=0.52$). There was no significant difference in terms of serious adverse events. The Prevention After Stroke – Blood Pressure (PAST-BP) trial (40) enrolled 529 participants from 99 General Practices in England identified from the practice’s TIA/stroke register. A total of 52% had suffered TIA and the remainder stroke. The type of stroke was not defined. Participants were randomised to intensive SBP reduction defined as SBP target <130 mmHg or a 10 mmHg reduction if baseline SBP was <140 mmHg versus standard SBP target (<140 mmHg). The primary outcome was change in SBP between baseline and 12 months. A recurrent stroke was observed in no participant in the intensive SBP target group versus 3 participants in the standard SBP target (RR 0.14, 95% CI 0.01 to 2.72). There was no difference between groups regarding major

1
2
3 vascular events, myocardial infarction, total death, or vascular death, as well as adverse
4
5 symptoms.

6
7
8 In the Recurrent Stroke Prevention Clinical Outcome Study (RESPECTS) (41), 1280
9
10 participants with a history of stroke <3 years (of whom 85% had a history of ischaemic stroke
11
12 and 15% had intracerebral haemorrhage) were randomised to intensive BP reduction (BP target
13
14 <120/80 mmHg) versus standard BP reduction (<140/90 mmHg or <130/80 mmHg for people
15
16 with diabetes, chronic kidney disease, or a history of myocardial infarction). The primary
17
18 endpoint (any recurrent stroke) was observed in 39 (1.65%) participants in the intensive
19
20 treatment group versus 52 (2.26%) in the standard treatment group after a mean follow-up of
21
22 3.9 years (HR 0.73, 95% CI 0.49 to 1.11). Intracerebral haemorrhage was less frequent in the
23
24 intensive BP reduction group (HR 0.09, 95% CI 0.01 to 0.70), whereas no difference was
25
26 observed for major vascular events, myocardial infarction, or all-cause death. Serious adverse
27
28 events were similar between the two groups.

29
30
31
32
33 Additionally, our literature search found a single-blinded trial conducted in South Korea by
34
35 Park et al (42). A total of 132 participants with a recent (7 to 42 days) ischaemic stroke related
36
37 to intracranial atherosclerotic stenosis were randomly allocated to intensive (SBP 110-120
38
39 mmHg) or standard (SBP 130–140 mmHg) BP control groups. The primary endpoint was the
40
41 white matter lesion volume change on MRI between baseline and 24 weeks. This did not differ
42
43 between groups. At 24 weeks, a new ischaemic stroke event was reported in 1 participant in
44
45 both the intensive and the standard BP reduction groups. There were no vascular deaths in the
46
47 study and the frequency of adverse events did not differ between the two groups.

48
49
50
51 Results for all considered outcomes and GRADE scoring, is available in Table 4. On meta-
52
53 analysis of data from 3 trials (39-41) there was a significant reduction in recurrent stroke with
54
55 intensive BP treatment compared with a standard BP reduction strategy (OR 0.79, 95% CI
56
57 0.64 to 0.98, p=0.029). There was no evidence of heterogeneity and the level of certainty was
58
59
60

rated as high. Use of an intensive blood pressure target would be expected to lead to 17 fewer cases of stroke per 1,000 treated. There was a non-significant reduction in ischaemic stroke with intensive BP treatment on meta-analysis of data from 3 trials (39, 41, 42) (OR 0.87, 95% CI 0.69 to 1.09, $p=0.228$).




Figure 4. Forest plot for the reduction in the risk of recurrent stroke after TIA or minor stroke in participants randomised to an intensive blood pressure lowering strategy (<130/80) vs a less intensive strategy (<140/90). Heterogeneity: I-squared=0.000; Q=1.509; $p=0.470$.

On meta-analysis of data from 2 trials (39, 41), there was a significant reduction in haemorrhagic stroke with intensive BP reduction (OR 0.25, 95% CI 0.07 to 0.90, $p=0.033$, table 4, figure 5). There was no significant difference between groups for the outcomes of major vascular events, myocardial infarction, all-cause death, or vascular death on meta-analysis (table 4). Finally, functional outcome was only assessed in the SPS3 trial (39). There was no significant difference between intensive and standard BP reduction groups for poor outcome defined as a mRS score ≥ 3 (OR 0.82, 95% CI 0.54 to 1.25).




Figure 5. Forest plot for the reduction in the risk of recurrent haemorrhagic stroke after TIA or stroke in participants randomised to an intensive blood pressure lowering strategy (<130/80) vs a less intensive strategy (<140/90). Heterogeneity: I-squared=36.402; Q=1.572; p=0.210

Additional Information

There was some heterogeneity between trials in terms of participants enrolled; SPS3 (39) only included people with lacunar stroke, PAST-BP (40) included people with TIA and stroke, RESPECTS (41) included people with haemorrhagic stroke, and Park’s trial focused on people with ischaemic stroke related to intracranial atherosclerotic stenosis. Outcomes were not reported according to baseline characteristics meaning it is difficult to generalize recommendations for specific subgroups. Other studies suggest caution regarding intensive BP reduction for some groups of people. For instance, pooled data from the European Carotid Surgery Trial (ECST) and the North American Symptomatic Carotid Endarterectomy Trial (NASCET) showed that there was a relationship between higher stroke risk and lower blood pressure in people with bilateral severe ($\geq 70\%$) internal carotid artery stenosis (43). In addition, the mean age of participants from the trials identified in our meta-analysis ranged between 63

1
2
3 and 72 years old, which is lower than that observed in population-based registries and in
4 clinical practice (44). This reflects the fact that elderly people were under-represented in
5 randomised clinical trials, particularly those with frailty (45). Indeed, in one study these
6 participants had a greater risk of stroke with intensive treatment (adjusted HR 1.93; 95% CI
7 1.04 to 3.60, $p=0.038$), without a difference in wider cardiovascular outcomes or all-cause
8 mortality, and an increased risk of hypotension and syncope (45). Considering that pre-existing
9 mild cognitive impairment is common in people with stroke (46, 47), additional research is
10 needed to clarify the best BP target in people with stroke and cognitive impairment. In general,
11 BP reduction in older people (aged > 80 years) can be expected to reduce risk of stroke as
12 shown in a large study of indapamide with or without an ACE inhibitor (48). Another issue is
13 the impact of intensive versus usual BP control on kidney function. A sub-analysis of SPS3
14 demonstrated a greater likelihood of rapid kidney function decline with intensive BP reduction,
15 although this was not associated with an increased risk of clinically important events (49). This
16 was also seen in the Systolic Blood Pressure Intervention Trial (SPRINT), where intensive BP
17 reduction was associated with a reduction in estimated glomerular filtration rate, although this
18 effect was outweighed by cardiovascular and all-cause mortality benefits (50), and the impact
19 on longer-term kidney outcomes remains to be determined. As such, a more cautious approach
20 to intensive blood pressure lowering may be warranted in people with bilateral, severe carotid
21 stenosis, older age, cognitive impairment or pre-existing renal disease. Overall, we rated the
22 quality of evidence as moderate, although it was high for the outcome of any stroke.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Evidence-based Recommendation

In people with previous ischaemic stroke or TIA, we suggest aiming for a blood pressure target of <130/80 mmHg to reduce the risk of recurrent stroke.

Quality of evidence: **Moderate** ⊕⊕⊕

Strength of recommendation: **Weak for intervention** ↑?

PICO question 4: In people with a history of ischaemic stroke or TIA starting antihypertensive therapy, does initiation of two blood pressure lowering medications compared to monotherapy reduce the risk of recurrent stroke?

Analysis of current evidence

The systematic review identified no trials in which initiation of a combination of antihypertensive medications was directly compared to initiation of a single agent in the secondary prevention of stroke or TIA, and no trial in which a specific combination of blood pressure lowering medications was compared to another combination of blood pressure lowering medications.

The perindopril protection against recurrent stroke (PROGRESS) trial was the only trial identified that randomised participants to a defined combination treatment, but the treating physician had discretion to choose whether monotherapy or combination treatment was used (21). As such, the perindopril and indapamide versus perindopril alone comparison is not a randomised comparison. In addition, the combination treatment arm was slightly more hypertensive at baseline. Nonetheless, combination treatment was associated with a greater reduction in blood pressure compared to placebo (12.5/5.0 mmHg) than monotherapy treatment versus placebo (4.9/2.8 mmHg), as well as a proportionately greater relative reduction in the risk of recurrent stroke (43% vs 5%).

Supporting information to the expert consensus statement

We conclude that in people with previous ischaemic stroke or TIA, there are insufficient data to provide a recommendation for the PICO question. Given that blood pressure lowering appears to have consistent effects in the setting of primary and secondary prevention with

1
2
3 regard to stroke, we used data from primary prevention studies to help us reach a consensus.
4
5 Trials have explored the use of combined therapy vs. monotherapy in people with essential
6
7 hypertension and show that this leads to better control of BP (51, 52). A large systematic
8
9 review and meta-analysis shows that the extra blood pressure reduction from combining two
10
11 drug classes is approximately 5 times greater than doubling the dose of one drug (53). Large
12
13 observational cohort studies have demonstrated that initiation of combination therapy is
14
15 associated with improved blood pressure control (53, 54) and improved adherence (55, 56)
16
17 compared with monotherapy and with minimal additional side-effects, associated with
18
19 significant reductions in clinical events compared to placebo (53). This evidence underpins
20
21 the current European Society of Hypertension and European Society of Cardiology guidelines
22
23 (57) which recommend initiation of antihypertensive treatment with combination treatment,
24
25 except in people at increased risk of hypotension and those with mild hypertension and low
26
27 cardiovascular risk (not applicable to our stroke population). In the absence of alternative
28
29 specific evidence for secondary prevention in stroke, and supportive evidence for the
30
31 potential benefit of combination treatment in PROGRESS (21), this European guidance is
32
33 therefore applicable for most people with prior stroke. Where possible, combination
34
35 treatment should be provided as a single tablet where possible, to improve adherence (58).
36
37
38 There is limited direct evidence to guide the choice of medications to use in a combination
39
40 regimen. In primary prevention trials, calcium channel blockers (CCBs) appear to be slightly
41
42 more efficacious than other classes in prevention of stroke, at the cost of an increased risk of
43
44 symptomatic heart failure (59, 60). This effect may be due to a greater consistency of blood
45
46 pressure control with CCBs and thiazide-like diuretics. In contrast, inhibitors of the renin
47
48 angiotensin system (RAS) are particularly effective in prevention of coronary artery disease
49
50 and renal dysfunction, and angiotensin receptor blockers (ARB) have an excellent side effect
51
52 profile (61). RAS inhibition plus a CCB was superior to RAS inhibition plus a diuretic in the
53
54
55
56
57
58
59
60

1
2
3 The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with
4 Systolic Hypertension (ACCOMPLISH) trial (62), but this was not confirmed in further less
5
6 well powered trials (63, 64). Therefore, based on primary prevention guidelines, plus
7
8 supportive evidence from drug classes used in trials such as PROGRESS, initiation of
9
10 treatment with a combination of antihypertensive medication, usually containing either a
11
12 thiazide-like diuretic (such as indapamide) or a CCB (such as amlodipine or felodipine),
13
14 combined with a RAS inhibitor (ACE inhibitor or angiotensin 2 receptor blocker) is
15
16 reasonable. If a third agent is needed, a CCB or thiazide can then be added if not already in
17
18 use. Further studies are required to determine optimal combinations, especially in secondary
19
20 prevention of stroke, or the potential benefit of three drug combinations, as is currently being
21
22 tested after intracerebral haemorrhage in the Triple Therapy Prevention of Recurrent
23
24 Intracerebral Disease EveNts (TRIDENT) trial (NCT02699645). The panel voted by 10 / 12
25
26 members for the following consensus statement (supplementary table 2).
27
28
29
30
31
32
33
34

35 **Evidence-based Recommendation**

36 -

37
38
39
40 Quality of evidence: -

41
42
43
44 Strength of recommendation: -

45
46
47
48
49 **Expert Consensus Statement**

50
51
52 In people with ischaemic stroke or TIA, we support initiation of a combination of two blood
53
54 pressure lowering drugs to reduce the risk of recurrent stroke, with consideration of
55
56 monotherapy where there are potential risks of hypotension, such as in frail, elderly people and
57
58 people with borderline hypertension
59
60

Lipid lowering therapy

PICO question 5: In people with ischaemic stroke or TIA does use of an HMGCoA reductase inhibitor compared to no lipid-lowering therapy reduce the risk of recurrent stroke?

Analysis of current evidence

Our systematic review and search of associated reference lists identified 1986 titles, of which 301 were reviewed in full. We found five trials (65-69) which directly addressed this PICO question. These trials included a total of 10,169 participants.

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial (66), which was published in 2006, included 4,731 participants who had had an ischaemic stroke or TIA within one to six months before study entry. Participants were randomised to receive either 80 mg atorvastatin daily or placebo. The primary outcome was any nonfatal or fatal stroke. The mean age of participants was 63 years and the mean duration of follow up was 4.9 years. There was a significant reduction in the primary outcome with atorvastatin 80 mg daily (adjusted HR 0.84, 95% CI 0.71 to 0.99).

The Heart Protection Study Collaborative (HPSC) (65), included 20,536 people aged between 40 and 80 years with non-fasting blood total cholesterol concentrations of at least 3.5 mmol/L (135 mg/dL). Of these, 3,280 had a history of prior cerebrovascular disease and these outcomes were reported separately; 63% of these had a history of non-disabling non-haemorrhagic stroke, 46% a history of TIA, 10% had undergone carotid endarterectomy and 2% carotid angioplasty. People with a stroke within the previous 6 months were excluded. In the main trial, participants were randomised to 40 mg simvastatin daily or placebo. The primary outcome was occurrence of any stroke. The mean age of participants was 65 years, the mean duration of follow up was 4.8 years and the mean interval since the most recent


1
2
3 stroke or TIA was 4.3 years. There was a significant reduction in the primary outcome with
4
5 simvastatin 40 daily (HR 0.75, 95% CI 0.66 to 0.85).
6

7
8 The Japan Statin Treatment Against Recurrent Stroke (J-STARS) trial, which was published
9
10 in 2015 (67), included 1,578 participants (although a sample size of 3,000 was initially
11
12 planned) aged 45 to 80 years with a history of non-cardioembolic ischaemic stroke within the
13
14 preceding one month to three years. Participants were randomised to receive pravastatin 10
15
16 mg daily or no HMGCoA reductase inhibitor therapy. The primary outcome was stroke
17
18 (expressed as rate (%) per year). The mean age of participants was 66 years and the mean
19
20 duration of follow up was 4.9 years. Stroke rate was similar between the two arms with an
21
22 annual rate of 2.4% with pravastatin vs. 2.5% in the comparison group (adjusted HR 0.95,
23
24 95% CI 0.71 to 1.28).
25
26
27

28
29 The Cholesterol and Recurrent Events (CARE) trial was a secondary prevention trial
30
31 comparing pravastatin 40 mg/day after myocardial infarction (68). A total of 4,159
32
33 participants aged between 21 and 75 years were enrolled after a mean of 10 months from the
34
35 index event. The median follow-up period was 5 years. A hundred participants in the placebo
36
37 group and 111 participants in the pravastatin group had a history of prior stroke/TIA.
38
39 HMGCoA reductase inhibitor treatment in this subgroup of participants led to a 37% relative
40
41 risk reduction in stroke or TIA (95% CI 23% to 68%) (68).
42
43
44

45
46 The LIPID (the Long-Term Intervention with Pravastatin in ischaemic Disease) trial
47
48 randomised 9,014 participants with a median age of 62 years and a history of myocardial
49
50 infarction or unstable angina during the previous 3 to 36 months to receive pravastatin 40
51
52 mg/day or placebo (69). Prespecified secondary end points included stroke from any cause.
53
54 The mean duration of follow-up was 6.1 years. A total of 610 participants (n=325 in the
55
56 intervention group) had a history of cerebrovascular disease. Pravastatin treatment in these
57
58 participants was associated with a relative risk of stroke of 0.72 (95% CI 0.46 to 1.12) (70).
59
60

Results for all considered outcomes and GRADE scoring is available in Table 5. On meta-analysis of data from 5 trials (65-69) there was a significant reduction in the rate of any stroke in people treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy (OR 0.89, 95% CI 0.78 to 0.99, $p=0.049$) with little heterogeneity among the trials ($I^2=0$, p for heterogeneity= 0.65). The level of certainty was rated as high. Data suggest that use of a HMGCoA reductase inhibitor would be expected to lead to 13 fewer cases of stroke per 1,000 treated.



Meta Analysis

Figure 6. Forest plot for the risk of any stroke in trials comparing treatment with HMGCoA reductase inhibitors versus placebo after TIA or stroke. Heterogeneity: $I^2=0.000$; Q -value= 2.473

Results were also consistent when the analysis was confined to the two trials that recruited participants early after their index ischaemic stroke (supplementary figure 1).

On meta-analysis of data from 2 trials (65, 71), there was a significant reduction in the rate of ischaemic stroke in people treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy (OR: 0.79, 95% CI 0.67 to 0.92; equivalent to 20 fewer events per 1000, 95% CI from 30 fewer to 7 fewer) (table 5). The level of certainty was rated as high.

On meta-analysis of data from 3 trials (65-67) there was a significant increase in the rate of haemorrhagic stroke in people treated with HMGCoA reductase inhibitors compared to no lipid-lowering therapy (OR: 1.55, 95% CI 1.09 to 2.21); equivalent to 6 more events per 1,000 (from 1 more to 14 more) (figure7, table 5). The level of certainty was rated as high.




Figure 7. Forest plot for the risk of haemorrhagic stroke in trials comparing treatment with HMGCoA reductase inhibitors versus placebo after TIA or stroke. I-

squared=4.423; q=2.093, p=0.351

On meta-analysis of data from 2 trials (65, 71) there was a significant reduction in the rate of any major cardiovascular event in people treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy (OR: 0.78, 95% CI 0.70 to 0.87); equivalent to 40 fewer per 1,000 (from 55 fewer to 22 fewer) (table 5). The level of certainty was rated as high.

1
2
3 Only one trial reported data on the rate of myocardial infarction (67). This showed that that
4 there was no significant reduction in the rate of myocardial infarction in people treated with a
5 HMGCoA reductase inhibitor compared to no lipid-lowering therapy (HR: 0.55, 95% CI 0.16
6 to 1.89); 4 fewer per 1,000 (from 7 fewer to 8 more). The level of certainty was rated as very
7 low due to imprecision.

8
9
10 On meta-analysis of data from 2 trials (67, 71) there was no reduction in the rate of death in
11 people treated with a HMGCoA reductase inhibitor compared to no lipid-lowering therapy
12 (OR 1.03, 95% CI 0.87 to 1.24) (table 5). There was also no significant reduction in
13 cardiovascular death (OR 0.78, 95% CI 0.58 to 1.06). The level of certainty was rated as low.

14
15 Only one trial reported data on the rate of dementia (67) . This showed that that there was no
16 significant reduction in the rate of dementia (OR 0.89, 95% CI 0.79 to 1.03). The level of
17 certainty was rated as very low.

30 **Additional information**

31
32 Overall, we rated the quality of evidence as high. High quality evidence suggests that use of a
33 HMGCoA reductase inhibitor reduces risk of ischaemic stroke and major cardiovascular
34 events in people with previous ischaemic stroke or TIA. The effect on myocardial infarction
35 in this population is less clear, although HMGCoA reductase inhibitors significantly reduce
36 the risk of myocardial infarction in other groups. Our analysis showed that the risk of
37 haemorrhagic stroke is increased with use of an HMGCoA reductase inhibitor. However,
38 analysis showed a trend toward a reduction in total stroke, and in cardiovascular death,
39 suggesting a net beneficial effect in people with previous ischaemic stroke and TIA. It is
40 important to note that the SPARCL trial included a small number of people with
41 haemorrhagic stroke, but the increase in haemorrhagic stroke during follow-up was still seen
42 when these participants were excluded from analyses. Therefore, even if this increase is real,
43 our data show that use of an HMGCoA reductase inhibitor may cause 6 haemorrhagic strokes
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

per 1000 people treated but prevent 40 major cardiovascular events. Participants in the SPARCL trial received atorvastatin 80mg daily and when this is considered alongside the data for PICO question 6 below, we believe this is an appropriate dose for most people with ischaemic stroke or TIA.

Evidence-based Recommendation

In people with previous ischaemic stroke or TIA we recommend use of a HMGCoA reductase inhibitor to reduce the risk of recurrent ischaemic stroke.

Quality of evidence: **High** ⊕⊕⊕⊕

Strength of recommendation: **Strong for intervention** ↑↑

PICO question 6: In people with ischaemic stroke or TIA does working to an intensive cholesterol treatment target, compared to a less intensive target, reduce the risk of recurrent stroke?

Analysis of current evidence

Our systematic review and search of associated reference lists identified 1986 titles, of which 301 were reviewed in full. We found one randomised trial which directly addressed this PICO question. The Treat Stroke to Target trial included 2,860 people with a stroke in the previous 3 months or a TIA within the previous 15 days (72). It was a parallel-group trial conducted in France and South Korea. Participants were randomised to an LDL target of <1.8 mmol/l (< 70 mg/dL) or to a target LDL of 2.3 to 2.8 mmol/l (90-110 mg/dL). Investigators were allowed to use any type or dose of HMGCoA reductase inhibitor or other lipid lowering therapy to reach these targets. The primary outcome was occurrence of a major

1
2
3 cardiovascular event. The median duration of follow up was 3.5 years. There was a higher
4
5 rate of HMGCoA reductase inhibitor use (94% vs. 66%) and a higher rate of combined
6
7 HMGCoA reductase inhibitor and ezetimibe use (35% vs 6%) in the low target group. The
8
9 study showed a significant reduction in the risk of major cardiovascular events (HR 0.78,
10
11 95% CI 0.61 to 0.98; P=0.04) in the intensive treatment group. There was a non-significant
12
13 reduction in risk of cerebral infarction or intracranial haemorrhage (HR 0.82, 95% CI 0.63 to
14
15 1.07). There were also non-significant reductions in MI, (HR 0.64, 95% CI 0.37 to 1.13),
16
17 cerebral infarction or TIA (HR 0.97, 95% CI 0.73 to 1.30), total mortality and cardiovascular
18
19 mortality (HR 0.69, 95% CI 0.40 to 1.18). There was a non-significant increase in intracranial
20
21 haemorrhage (HR 1.38, 95% CI 0.68 to 2.82).
22
23
24
25
26
27
28

29 **Additional information**

30
31 Post hoc analyses give further information concerning the benefits of intensive control of
32
33 LDL cholesterol levels. Analysis from the Treat Stroke to Target trial showed that
34
35 participants achieving LDL cholesterol <1.8 mmol/l (<70 mg/dL) had a lower risk of
36
37 ischaemic stroke (OR 0.74, 95% CI 0.55 to 0.99) (72). In a post-hoc analysis of the SPARCL
38
39 trial (71), participants with a LDL cholesterol reduction of $\geq 50\%$ from baseline had a 35%
40
41 reduction in the risk of all stroke (HR 0.65, 95% CI 0.52 to 0.81). In a post hoc analysis of
42
43 the J-STARS study (73), participants were divided into groups according to post-randomised
44
45 LDL cholesterol levels (i.e. <2.1 mmol/l (80 mg/dl) (n=89), 2.1-2.6 mmol/l (80–100 mg/dl)
46
47 (n=319), 2.6-3.1 mmol/l (100–120 mg/dl) (n=478), 3.1-3.6 mmol/l (120–140 mg/dl) (n=419),
48
49 ≥ 3.6 mmol/l (140 mg/dL) (n=212)). The HR for stroke and TIA was lower with a post
50
51 randomised LDL cholesterol level of 2.1 to 2.6 mmol/l (80 to 100 mg/dl) (p=0.23, for the
52
53 trend) after adjustment for baseline LDL cholesterol, body mass index, hypertension, diabetes
54
55
56
57
58
59
60

mellitus and HMGCoA reductase inhibitor usage. Overall, we rated the level of certainty as moderate for this PICO question.

Evidence-based Recommendation

In people with ischaemic stroke or TIA, we recommend aiming for an LDL cholesterol level of <1.8 mmol/l (70 mg/dl) to reduce the risk of major cardiovascular events.

Quality of evidence: **Moderate** ⊕⊕⊕

Strength of recommendation: **Strong for intervention** ↑↑

PICO question 7: In people with a previous ischaemic stroke or TIA who do not achieve recommended LDL-C targets despite taking a maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, is the addition of ezetimibe and/or a PCSK9-inhibitor superior to an HMGCoA reductase inhibitor alone to reduce the risk of recurrent stroke?

Analysis of current evidence

Our systematic review and search of associated reference lists identified 1986 titles, of which 301 were reviewed in full. We did not identify any randomised controlled trial that directly compared the add-on therapy with ezetimibe and/or PCSK-9 inhibitor vs. HMGCoA reductase inhibitor alone in people with a history of ischaemic stroke or TIA. However, subgroup analyses of three randomised clinical trials, mostly in people with coronary heart disease (74-76) have indirectly addressed the PICO question, albeit with limited precision due to small number of outcomes.

The Improved Reduction of Outcomes: Vytarin Efficacy International (IMPROVE-IT) trial (75) was a double-blinded, randomised trial involving 18,144 participants who were hospitalised for a recent acute coronary syndrome who had a LDL cholesterol level between

1
2
3 1.3-3.2 mmol/l (50-125 mg/dl) if not taking lipid lowering therapy or a LDL level between
4
5 1.3-2.6 mmol/l (50-100 mg/dl) if they were. Participants were randomised to ezetimibe plus
6
7 simvastatin vs. placebo plus simvastatin. Ezetimibe led to a significant relative reduction of
8
9 major cardiovascular events (7-year risk 32.7% vs. 34.7%; HR 0.94, 95% CI 0.89 to 0.99,
10
11 p=0.016). The effect appeared to be consistent for any stroke (HR 0.86, 95% CI 0.73 to 1.00,
12
13 p=0.05) and for ischaemic stroke (HR 0.79, 95% CI 0.67 to 0.94, p=0.008), without a
14
15 significant increase in haemorrhagic stroke (HR 1.38, 95% CI 0.93 to 2.04, p=0.11). A small
16
17 number of participants (n=682, 3.8% of trial population) had a history of stroke at
18
19 baseline.(77) The mean age was 68 years, with 29% being female. The baseline mean LDL
20
21 was 87 mg/dl (2.2 mmol/l). In the subgroup of people with previous stroke, the results were
22
23 consistent with the main analysis. There was a non-significant reduction of major
24
25 cardiovascular disease with ezetimibe compared to placebo (HR 0.78, 95% CI 0.59 to 1.02).
26
27 There was a significant reduction in risk of any stroke (HR 0.60, 95% CI 0.38 to 0.95), and
28
29 ischaemic stroke (HR 0.52, 95% CI 0.31 to 0.86) but there were only 77 outcomes. There was
30
31 no reduction in myocardial infarction (HR 0.85, 0.59 to 1.24), all-cause mortality (HR 0.96,
32
33 95% CI 0.71 to 1.30) or cardiovascular death (HR 1.11, 95% CI 0.70 to 1.76). There was no
34
35 significant increase in haemorrhagic stroke (HR 1.69, 95% CI 0.40 to 7.06).

36
37
38
39
40
41
42 The Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During
43
44 Treatment With Alirocumab (ODYSSEY outcomes) trial was a multicentre, randomised,
45
46 double-blind, placebo-controlled trial (74) comparing alirocumab, which is a human
47
48 monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), vs. placebo in
49
50 18,924 participants aged 40 years or older, who had been hospitalised with an acute coronary
51
52 syndrome 1-12 months before randomisation. Baseline lipid levels were measured after a
53
54 minimum of 2 weeks of treatment with moderate or high intensity HMGCoA reductase
55
56 inhibitors or the maximum tolerated dose of these HMGCoA reductase inhibitors.
57
58
59
60

1
2
3 Participants all had an LDL cholesterol level of at least 1.9 mmol/l (70 mg/dl), a non-HDL
4 cholesterol level of at least 2.6 mmol/l (100 mg/dl) or an apolipoprotein B level of at least 80
5 mg/dl. The trial found that alirocumab reduced the risk of recurrent ischaemic cardiovascular
6 events (4-year risk=12.5% vs. 14.5%; hazard ratio HR 0.85, 95% CI 0.73 to 0.98) compared
7 to placebo. Moreover, alirocumab also reduced the risk of fatal or nonfatal ischaemic stroke
8 by 27% (HR 0.73, 95% CI 0.57 to 0.93) without increasing the risk of haemorrhagic stroke
9 (HR 0.83, 95% CI 0.42 to 1.65) (78). In ODYSSEY outcomes, there were 944 patients
10 (5.0%) who also had a history of cerebrovascular disease at baseline.(71) In this subgroup,
11 the mean age was 63 years and approximately a third were women (31.9%). Baseline mean
12 LDL was 91 mg/dl (2.4 mmol/l) and 84.7% were on a high-intensity HMGCoA reductase
13 inhibitor. Although the trend was consistent with the overall study result, based on 51
14 outcomes, there was no significant reduction in stroke with alirocumab (HR 0.90, 95% CI
15 0.52 to 1.56).

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33 The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with
34 Elevated Risk (FOURIER) trial (76) was a multinational, randomised, double-blind, placebo-
35 controlled trial comparing evolocumab, another monoclonal antibody that inhibits PCSK9, to
36 placebo in 27,564 high-risk people aged 40 to 85 years with a history of myocardial
37 infarction, non-haemorrhagic stroke or symptomatic peripheral artery disease. All
38 participants had a baseline LDL of 70 mg/dl (1.8 mmol/l) or more, or a non-HDL cholesterol
39 level of at least 100 mg/dl (2.6 mmol/l) whilst on optimised lipid lowering therapy. In the
40 whole intention-to-treat population, evolocumab reduced risks of major cardiovascular events
41 by 15% (9.8% vs. 11.3%; HR 0.85, 95% CI 0.79 to 0.92) compared to placebo. Of note,
42 evolocumab was also associated with a 25% reduction in risks of ischaemic stroke (HR 0.75,
43 95% CI 0.62 to 0.92) without a significant increase in haemorrhagic stroke (HR 1.16, 95% CI
44 0.68 to 1.98). In line with the main results, among the subgroup of 5337 (19%) participants
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

who had a history of ischaemic stroke at baseline (mean age 65 years, 22.2% female, mean LDL=2.4 mmol/l), evolocumab was associated with a 15% reduction of major cardiovascular events (HR 0.85, 95% CI 0.72 to 1.00) compared to placebo, driven by a reduction in myocardial infarction (HR 0.74, 95% CI 0.55 to 1.00).⁽⁷²⁾ However, based on 200 outcomes in total, there was no significant reduction in risk of recurrent stroke (HR 0.90, 95% CI 0.68 to 1.19), recurrent ischaemic stroke (HR 0.92, 95% CI 0.68 to 1.25), haemorrhagic stroke (HR 0.99, 95% CI 0.47 to 2.07), or cardiovascular death (HR 1.11, 95% CI 0.80 to 1.56).⁽⁷²⁾⁽⁷⁹⁾

Results for all considered outcomes and GRADE scoring, is available in Table 6.

On meta-analysis of data from the subgroup of participants with history of cerebrovascular disease from the above three trials (74-76), there was no significant reduction in any stroke with add-on therapy with ezetimibe and/or PCSK9-inhibitor (HR 0.81, 95% CI 0.64 to 1.04).

The level of certainty was rated as low.




Figure 8. Forest plot for the risk of recurrent stroke in trials comparing treatment with PCSK9 inhibitors versus placebo after TIA or stroke. Heterogeneity: I-squared=13.843; Q-value=2.321,p=0.313

On meta-analysis of data from 2 trials (77, 79), there was no significant reduction in ischaemic stroke (HR 0.72, 95% CI 0.41 to 1.25, table 6) with add on therapy and there was no difference in rate of haemorrhagic stroke (HR 1.11, 0.57 to 2.14; table 6). The level of certainty for these outcomes was rated as low.

On meta-analysis of data from 2 trials (77, 79), there was a significant reduction in major cardiovascular events (HR 0.83, 95% CI 0.72 to 0.96; table 6, figure 9) and myocardial infarction (HR 0.78, 95% CI 0.62 to 0.99); table 6) with add on therapy. There was little evidence of heterogeneity, and the level of certainty was rated as high.




Figure 9. Forest plot for the risk of any major cardiovascular event in trials comparing treatment with PCSK9 inhibitors versus placebo after TIA or stroke. Heterogeneity: I-squared=0.000; Q=0.278;p=0.598

Additional information

As mentioned in PICO question 6, the recent Treat Stroke to Target trial showed that a lower target LDL cholesterol <70 mg/dl (1.8 mmol/l) was superior to a target of 90-110 mg/dl (2.3-2.8 mmol/l) for preventing major cardiovascular events in participants with ischaemic stroke or TIA with evidence of atherosclerosis.(72) There is also evidence that each 1.0 mmol/l

1
2
3 reduction in LDL (39 mg/dl) reduces the risks of major vascular events by about one
4
5 fifth.(80) This effect is also seen for the prevention of any stroke in wider populations of
6
7 people at risk of cardiovascular disease.(81) However, there is a lack of direct evidence in
8
9 the stroke population. Overall, we rated the level of certainty as low.
10
11
12
13

14 **Supporting information to the expert consensus statement**

15
16
17 There is insufficient evidence to support a recommendation concerning add-on therapy with
18
19 ezetimibe and/or PCSK9-inhibitor to reduce risk of recurrent stroke in people with ischaemic
20
21 stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally
22
23 tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks. This was due to
24
25 imprecision and potential selection bias as all data are derived from subgroup analyses of
26
27 trials. However, there is some evidence, albeit indirect for the TIA and ischaemic stroke
28
29 population, that the addition of ezetimibe and/or PCSK-9 inhibitor is superior to HMGCoA
30
31 reductase inhibitor alone to reduce the overall risk of recurrent major cardiovascular events in
32
33 this population. Moreover, there is evidence that a more intensive cholesterol treatment target
34
35 compared to a less intensive target, which includes use of ezetimibe in some people, reduces
36
37 the risk of recurrent ischaemic stroke and major cardiovascular events. The use of a PCSK9
38
39 inhibitor could be considered in people who have ischaemic heart disease, or who have
40
41 ischaemic stroke and would have met the criteria for the FOURIER trial, where LDL targets
42
43 cannot be obtained using a HMGCoA reductase inhibitor and ezetimibe. The panel voted by
44
45 12 / 12 members for the following consensus statement (supplementary table 2).
46
47
48
49
50
51
52
53

54 **Evidence-based Recommendation**

55 -

56
57
58 Quality of evidence: -
59
60

Strength of recommendation: -

Expert Consensus Statement

In people with ischaemic stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, we support the addition of ezetimibe as an option to reduce the risk of recurrent major cardiovascular events.

Anti-thrombotic therapy

PICO question 8: In people with ischaemic stroke or TIA, does long-term antiplatelet therapy compared to no antiplatelet therapy reduce the risk of recurrent stroke?

Analysis of current evidence

The literature search identified 6332 titles and 645 full texts were identified for review. For this PICO question, 11 studies and a total of 13,369 participants were included (82-92). Eight trials compared aspirin to placebo (82-89), one trial compared cilostazol with placebo (92) and one compared ticlopidine vs placebo (91). One trial compared aspirin and dipyridamole to placebo (87) and one trial included an aspirin and dipyridamole arm as well as an aspirin monotherapy arm (90). For our quantitative synthesis we only included data on antiplatelet monotherapy in our primary analysis as the use of dual antiplatelet therapy was addressed in PICO question 9. We explored whether inclusion of data from the European Stroke Prevention Study (ESPS) trial would materially alter the conclusions in an additional analysis because this compared aspirin and dipyridamole with placebo. Time from index event to inclusion in the study ranged from 1 week to one year, with the majority being

1
2
3 within 3 months. Follow-up ranged between 2 to 7 years (mean 2 years). The dose of aspirin
4 used ranged from 50 mg to 1300 mg daily.
5

6
7
8 The Trial of Aspirin in Transient Ischemia (AITIA) Trial (82) was a double-blind RCT
9 including 178 participants with a TIA or retinal occlusion who were randomised to either
10 aspirin 1300 mg or placebo. The primary outcome was mortality, cerebral or retinal infarction
11 and follow-up was for 2 years. There was no difference between groups in the rate of the
12 primary outcome.
13
14

15
16
17 The Canadian cooperative study (83, 84) was a double-blind RCT including 585 participants
18 with 'threatened stroke' who were randomised to either aspirin 1300 mg, sulfinpyrazone 800
19 mg, both these drugs or placebo. The mean follow-up was 26 months and the primary
20 outcome was TIA, stroke or death. There was a significant reduction in the primary outcome
21 in the aspirin group.
22
23

24
25
26 The Accidents Ischimiques Cerebraux Lies a L'Atherosclerose (AICLA) trial (84) was a three
27 arm double blind study in people with a recent TIA or cerebral infarction. Participants were
28 randomised to receive either aspirin (1000 mg), aspirin and dipyridamole (1000 mg+225 mg)
29 or placebo. Follow-up was for 3-years and the primary outcome was cerebral infarction.
30 Treatment with aspirin and treatment with aspirin plus dipyridamole reduced the risk of
31 stroke compared to placebo.
32
33

34
35
36 The Danish cooperative study (85) was a randomised double-blinded study of 203
37 participants comparing aspirin (1000 mg) with placebo. Mean follow-up was 25-months and
38 the primary outcome was stroke or death. The study did not find any statistical difference
39 between groups.
40
41

42
43
44 The Swedish cooperative study (86) was a double-blind placebo controlled trial of 1500 mg
45 aspirin daily vs. placebo in 505 participants within 3-weeks of cerebral infarction.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Participants were followed for up to 2 years and the primary outcome were stroke or death.

4
5 The study showed no difference between groups.

6
7
8 The UK-TIA trial (88) randomised 2435 participants with TIA or minor stroke to either
9
10 aspirin 300 mg or 1200 mg or placebo in a double-blinded study with a mean follow-up of 4
11
12 years. The primary outcome was major stroke, myocardial infarction and vascular death.

13
14 There was a significant reduction in the primary endpoint with aspirin treatment.

15
16
17 The Swedish Aspirin Low-Dose Trial (SALT) collaboration (89) was a double-blinded study
18
19 which randomised participants to aspirin (75 mg) vs placebo. The mean duration of follow up
20
21 was 32 months. The primary outcome was occurrence of stroke or death and there was a
22
23 significant reduction with aspirin treatment.

24
25
26 ESPS 2 (90) was a four-arm double-blinded randomised trial of aspirin 50 mg, dipyridamole
27
28 400 mg, aspirin plus dipyridamole (50 + 400 mg) or placebo. Follow up was for two years
29
30 and the primary endpoint was stroke or death. The study found a significant benefit of all the
31
32 antiplatelet strategies.

33
34
35 The Canadian American ticlopidine study (CATS) randomised 1072 people between 1 week
36
37 and 4 months after an ischaemic stroke to ticlopidine (250mg bd) or placebo, for up to 3
38
39 years (91). The primary outcome was a composite of stroke, myocardial infarction or
40
41 vascular death. There was a significant reduction in the primary outcome from 15.3% in the
42
43 placebo group to 10.8% in the ticlopidine group (RRR 30.2%, 95% CI 7.5 to 48.3%,
44
45 p=0.006).

46
47
48 The ESPS study (87) randomised 2500 participants to either aspirin 990 mg plus dipyridamole
49
50 225 mg or placebo in a double blinded study. Participants were followed for 2-years, and the
51
52 primary outcome was stroke or death. There was a significant reduction in the primary
53
54 outcome with aspirin and dipyridamole.

The cilostazol stroke prevention study (CSPS) was a double-blind randomised trial testing cilostazol vs placebo (92) on 1095 participants. The primary outcome was recurrence of cerebral infarction. There was a 41.7% relative risk reduction with cilostazol (95% CI 9.2 to 62.5%, $p=0.015$).

Results from meta-analysis for all outcomes and GRADE scoring, is available in Table 7. On meta-analysis of data from 9 trials (82, 84-86, 88-92) antiplatelet therapy reduced the risk of any stroke (OR 0.82, 95% CI 0.73 to 0.92, $I^2=0\%$, figure 10, table 7). The level of certainty was rated as high. Use of an antiplatelet would be expected to lead to 24 fewer cases of stroke per 1,000 treated.

On meta-analysis of data from 5 trials (82, 84-86, 89), antiplatelet therapy reduced the risk of ischaemic stroke (OR 0.67, 95% CI 0.54 to 0.85, $I^2=11.4\%$, $p=0.001$, table 7).





Figure 10. Forest plot for the risk of any stroke in trials comparing treatment with an antiplatelet versus placebo after TIA or stroke. $I^2=0.000$; $q=6.075$, $p=0.639$.

With ESPS1 included, OR = 0.78 (0.68-0.89).

On meta-analysis of data from 7 trials (84, 86, 88-92), antiplatelet therapy reduced the risk of major cardiovascular events (OR 0.78, 95% CI 0.67 to 0.90, I-squared=44%, figure 11, table 7).



Meta Analysis

Figure 11. Forest plot for the risk of major cardiovascular events in trials comparing treatment with an antiplatelet versus placebo after TIA or stroke. I-squared=44.134; q=10.740; p=0.097

On meta-analysis of data from 4 trials (82, 84, 86, 89) including 2718 participants, antiplatelet therapy did not significantly increase the risk of haemorrhagic stroke (OR 1.93, 95% CI 0.78 to 4.76, I-squared=0%, table 7) but the level of certainty was rated as low. On meta-analysis of data from 3 trials (89-91), antiplatelet therapy increased the risk of a major bleeding episode (OR 2.51, 95% CI 1.42 to 4.42, I-squared=0%, p=0.002, table 7). Use of an antiplatelet would be expected to lead to 9 more cases of major bleeding per 1,000 treated.

1
2
3 On meta-analysis of data from 9 trials (82, 84-86, 88-92), antiplatelet therapy reduced the risk
4 of myocardial infarction (OR 0.77, 95% CI 0.61 to 0.98, I-squared=0%, p=0.56 table 7). On
5 meta-analysis of data from 10 trials (82-85, 87-92) including 10869 participants, antiplatelet
6 therapy did not significantly reduce the risk of death (OR 0.90, 95% CI 0.80 to 1.02, I-
7 squared=0%, p=0.107, table 7). On meta-analysis of data from 9 trials (82-86, 88, 89, 91, 92)
8 including 7471 participants, antiplatelet therapy did not significantly reduce the risk of
9 cardiovascular death (OR 0.94, 95% CI 0.79 to 1.13, I-squared=0%, table 7) or improve
10 functional outcome (OR 1.01, 95% CI 0.72 to 1.42). There were no data concerning the effect
11 on risk of dementia.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Additional information**

27
28 Most of the included studies tested aspirin antiplatelet therapy. Previous other meta-analyses
29 have found results consistent with our findings. In 1994, the Antiplatelet Trialists
30 Collaboration published a collaborative and comprehensive overview of antiplatelet therapy
31 trials up to March 1990 (93). They concluded there was a significant benefit from antiplatelet
32 use in people with stroke and found the optimal dose of aspirin was 75-325 mg/day based on
33 limited additional benefit of higher doses but increased bleeding risk. Our results were
34 similar with and without inclusion of data from the ESPS trial.
35
36
37
38
39
40
41
42
43
44

45 Since these studies were conducted, a number of new antiplatelets have been developed and
46 studied in people with stroke. Broadly, these studies suggest that they are of at least similar
47 benefit to aspirin. For example, in the PRoFESS trial, there was a similar rate of recurrent
48 stroke with aspirin and dipyridamole (9%) than with clopidogrel (8.8%) (HR 1.01, 95% CI
49 0.92 to 1.11). Our recommendations cover use of antiplatelet therapy generally and choice of
50 drug regimen may differ in some regions. Overall, we rated the quality of evidence as being
51 moderate as, while it was high for any stroke, ischaemic stroke and major cardiovascular
52
53
54
55
56
57
58
59
60

1
2
3 events, it was low for haemorrhagic stroke due to imprecision and moderate for major
4
5 bleeding.
6
7
8
9

10 **Evidence-based Recommendation**

11
12 In people with previous ischaemic stroke or TIA, we recommend long-term use of antiplatelet
13 therapy to reduce the risk of recurrent stroke.
14
15

16
17
18
19 Quality of evidence: **Moderate** ⊕ ⊕ ⊕

20
21
22 Strength of recommendation: **Strong for intervention** ↑ ↑
23
24

25
26
27
28
29 **PICO question 9: In people with TIA and ischaemic stroke, does treatment with dual**
30 **antiplatelet therapy for longer than 90 days with aspirin plus clopidogrel or aspirin plus**
31 **dipyridamole, compared to a single antiplatelet, reduce the risk of recurrent stroke?**
32
33

34
35
36
37
38 **Analysis of current evidence**

39
40 The literature search identified 6332 titles and 645 full texts were identified. For this specific
41 PICO question, 6 studies (90, 94-98) and a total of 41,309 participants were included in the
42 qualitative and quantitative synthesis. This PICO question does not address use of dual
43 antiplatelets early after minor ischaemic stroke and TIA.
44
45
46
47
48

49 The Management of Atherothrombosis with Clopidogrel in High-risk patients (MATCH) trial
50 (94) enrolled 7599 people with ischaemic stroke or TIA in the previous 3 months, with one or
51 more of five risk factors (history of ischaemic stroke, history of myocardial infarction, angina
52 pectoris, diabetes mellitus, or symptomatic peripheral arterial disease). Participants were
53
54
55
56
57
58
59 randomised to clopidogrel 75 mg daily and aspirin 75 mg daily or clopidogrel 75 mg daily
60

1
2
3 and placebo. The duration of follow-up was 18 months. In the dual antiplatelet (DAPT) arm,
4
5 the RRR for any stroke was 2.0% (95% CI -13.8% to 15.6%), for ischaemic stroke was 7.1%
6
7 (95% CI -8.5% to 20.4%) and for major cardiovascular events was 5.9% (95% CI -7.1% to
8
9 17.3%). The absolute risk increase in major bleeding was 1.36% (95% CI 0.86% to 1.86%).
10
11 Two trials (95, 96) compared aspirin and clopidogrel with aspirin and placebo. The
12
13 Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization Management and
14
15 Avoidance (CHARISMA) trial (95) enrolled 15,603 people with multiple atherothrombotic
16
17 risk factors, coronary disease, cerebrovascular disease, or symptomatic peripheral arterial
18
19 disease. Participants were randomised to aspirin in a daily dose ranging from 75 mg to 162
20
21 mg and clopidogrel 75 mg daily or aspirin and placebo. In participants with cerebrovascular
22
23 disease, median follow-up was 2.1 years. In the DAPT arm, the HR for any stroke was 0.80
24
25 (95% CI 0.62 to 1.03), for ischaemic stroke it was 0.80 (95% CI 0.60 to 1.05), for
26
27 haemorrhagic stroke it was 1.11 (95% CI 0.45 to 2.74), and for major cardiovascular events it
28
29 was 0.84 (95% CI 0.69 to 1.03). The SPS3 trial (96) enrolled people with a recent lacunar
30
31 infarct. Participants were randomised to aspirin 325 mg daily and clopidogrel 75 mg daily or
32
33 aspirin 325 mg daily and placebo. The mean duration of follow-up was 3.4 years. In the
34
35 DAPT arm, HR for any stroke was 0.92 (95% CI 0.72 to 1.16), for ischaemic stroke it was
36
37 0.82 (95% CI 0.63 to 1.09), for haemorrhagic stroke it was 1.65 (95% CI 0.83 to 3.31), and
38
39 for major cardiovascular events it was 0.89 (95% CI 0.72 to 1.11).
40
41 Three trials (90, 97, 98) compared aspirin and extended-release (ER) dipyridamole versus
42
43 single antiplatelet therapy. The PRoFESS trial (98) enrolled 20322 people with an ischaemic
44
45 stroke within the prior 3 months. Participants were randomised to aspirin 25 mg daily and
46
47 dipyridamole 200 mg twice daily or clopidogrel 75 mg daily. The median duration of follow-
48
49 up was 25 months for participants with cerebrovascular disease. In the DAPT arm, the HR for
50
51 any stroke was 1.01 (95% CI 0.92 to 1.11), for ischaemic stroke it was 0.80 (95% CI 0.60 to
52
53
54
55
56
57
58
59
60

1
2
3 1.05), for intracranial haemorrhage it was 1.42 (95% CI 1.11 to 1.83), and for major
4
5 cardiovascular events it was 0.99 (95% CI 0.92 to 1.07).
6

7
8 The ESPS-2 trial (90) enrolled 6602 people with ischaemic stroke or TIA within the
9
10 preceding 3 months. Participants were randomised to aspirin 50 mg daily, or modified-release
11
12 dipyridamole 400 mg daily, both these drugs combined, or placebo. In the original
13
14 publication, stroke was not divided into haemorrhagic and ischaemic subtypes. Here, we
15
16 consider the comparison of aspirin combined with dipyridamole versus aspirin alone. We
17
18 computed the ORs based on the crude rates published. In the DAPT arm, compared to aspirin
19
20 alone, the OR for any stroke was 0.74 (95% CI 0.59 to 0.92) and for major cardiovascular
21
22 events it was 0.74 (95% CI 0.61 to 0.90). (90)
23
24
25

26 The European/Australasian Stroke Prevention in Reversible Ischaemia (ESPRIT) trial (97)
27
28 enrolled 2739 people within 6 months of a non-disabling ischaemic stroke and TIA.
29
30 Participants were randomised to aspirin (30–325 mg daily) and dipyridamole 400 mg daily or
31
32 aspirin alone. The mean duration of follow up was 3.5 years. In the DAPT arm, the OR for
33
34 ischaemic stroke was 0.82 (95% CI 0.62 to 1.09), the OR for major adverse cardiovascular
35
36 events was 0.76 (95% CI 0.60 to 0.95), and the OR for death was 0.87 (95% CI 0.65 to 1.16).
37
38 Results for meta-analysis of all outcomes and GRADE scoring are shown in table 8. In the
39
40 meta-analysis including 5 randomised controlled trials (90, 94-96, 98), use of dual
41
42 antiplatelets did not significantly reduce the risk of recurrent stroke (figure 12, table 8), but
43
44 there was a significant reduction in the risk of ischaemic stroke (OR = 0.92, 95% CI 0.85 to
45
46 0.99, table 8). The level of certainty was rated as very low due to imprecision and
47
48 inconsistency.
49
50
51
52
53
54
55
56
57
58
59
60





Figure 12. Forest plot for the risk of recurrent stroke in trials comparing treatment with dual versus single antiplatelets for more than 90 days after TIA or stroke.

Heterogeneity I-squared= 57.089; q=9.322, p=0.054.

However, in 3 randomised controlled trials (95, 96, 98), use of dual antiplatelets was associated with a significantly increased risk of haemorrhagic stroke (figure 13, table 8). The level of certainty was rated as high. The use of DAPT would be expected to lead to 4 more cases of haemorrhagic stroke per 1,000 treated.



Meta Analysis

Figure 13. Forest plot for the risk of haemorrhagic stroke in trials comparing treatment with dual versus single antiplatelets for more than 90 days after TIA or stroke.

Additional information

Overall, we rated the quality of evidence as being very low. Three trials assessed clopidogrel and aspirin dual anti-platelet therapy and three assessed aspirin and dipyridamole dual anti-platelet therapy. There was no evidence of net benefit of dual anti-platelet therapy in the trials of clopidogrel and aspirin therapy. There was no benefit of aspirin and dipyridamole therapy compared to clopidogrel in the PRoFESS trial but risk of intracerebral haemorrhage was increased. Adverse events and discontinuation of treatment were also more common with aspirin and dipyridamole. The ESPRIT and ESPTS-2 trials showed benefit from aspirin and dipyridamole compared to aspirin for some outcomes. Network meta-analyses have attempted to establish the best long-term anti-platelet therapy and suggest that clopidogrel or aspirin and dipyridamole in combination are the best strategies (99). We performed additional analyses to assess whether the effect of dual antiplatelet therapy with aspirin and clopidogrel appears similar to that of aspirin and dipyridamole. Note there are no head-to-head comparisons of these strategies. Results were broadly consistent for the outcomes of any stroke and

1
2
3 haemorrhagic stroke but rates of any major bleeding episode with aspirin and clopidogrel were
4
5 higher than with monotherapy (supplementary figures 2 and 3). However, these analyses were
6
7 limited by heterogeneity. Overall, we conclude that the evidence favours use of antiplatelet
8
9 monotherapy and indirect data suggest that clopidogrel is preferable to aspirin. Local practice
10
11 regarding the choice of agent differs across Europe.
12
13
14
15
16

Evidence-based Recommendation

17
18
19 In people with previous ischaemic stroke or TIA, we recommend against use of dual
20
21 antiplatelet therapy with aspirin and clopidogrel in the long-term and recommend use of single
22
23 antiplatelet to reduce the risk of recurrent stroke.
24
25

26
27 Quality of evidence: **Very Low** ⊕

28
29 Strength of recommendation: **Weak against intervention** ↓?
30
31
32

33
34 **PICO Question 10: In people with ischaemic stroke or TIA and atherosclerosis, with no**
35
36 **other indication for anticoagulation, does antiplatelet therapy combined with a low-dose**
37
38 **direct oral anticoagulant compared to antiplatelet therapy alone reduce the risk of**
39
40 **recurrent stroke?**
41
42
43
44

Analysis of current evidence

45
46
47 The literature search identified 6332 titles and 645 full texts were identified. No randomised
48
49 trials were found which directly addressed this PICO question in this population.
50

51
52 One trial addressed this treatment in people with other types of cardiovascular disease. The
53
54 Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) included
55
56 27,395 people with stable atherosclerotic disease (100). Participants had either a history of
57
58 coronary artery disease or peripheral vascular disease. Participants with coronary artery
59
60

1
2
3 disease who were less than 65 years of age were required to have arterial disease in 2
4
5 vascular beds or have 2 additional risk factors, one of which could be non lacunar ischaemic
6
7 stroke > 1 month ago. The definition of peripheral arterial disease included history of
8
9 previous carotid revascularisation or an asymptomatic carotid artery stenosis of >50%.
10
11 People with a history of stroke within one month or any history of haemorrhagic or lacunar
12
13 stroke were excluded. In total, 3.8% of trial participants had a history of previous stroke. A
14
15 total of 7470 people were enrolled with a history of peripheral vascular disease and 26% of
16
17 these had a history of previous carotid artery disease or asymptomatic carotid artery
18
19 stenosis >50%.
20
21
22

23
24 The trial compared three treatment strategies. These were rivaroxaban 2.5 mg twice daily
25
26 plus aspirin 100 mg, rivaroxaban 5 mg twice daily, and aspirin 100 mg daily. The
27
28 combination of rivaroxaban plus aspirin reduced the risk of the primary outcome of
29
30 cardiovascular death, stroke, or myocardial infarction compared to aspirin alone (HR 0.76,
31
32 95% CI 0.66 to 0.86, $P < 0.001$). Rivaroxaban was not superior to aspirin alone. The risk of
33
34 stroke was reduced by the combination of rivaroxaban plus aspirin compared to aspirin alone
35
36 (HR 0.58, 95% CI 0.44 to 0.76) with an absolute risk reduction of 0.7%. The risk of
37
38 ischaemic stroke was also reduced (HR 0.51, 95% CI 0.38 to 0.68). There was no significant
39
40 increase in the risk of haemorrhagic stroke (HR 1.49, 95% CI 0.67 to 3.31) but there were
41
42 few events and a potentially important increase cannot be excluded. An exploratory analysis
43
44 showed that the combination of rivaroxaban plus aspirin reduced the risk of cardioembolic
45
46 stroke and embolic stroke of undetermined source (101). In subgroup analyses of participants
47
48 with a history of peripheral artery disease, and in those with carotid artery disease, the results
49
50 were consistent with those from the whole study population (102). In a subgroup analysis of
51
52 people with previous stroke results were also similar but this was based on a small number of
53
54 events (n=29) (103).
55
56
57
58
59
60

1
2
3 A recent systematic review and meta-analysis on low dose direct oral anticoagulation therapy
4 combined with antiplatelet therapy in people with cardiovascular disease included seven
5
6 randomised trials (104). In addition to the COMPASS trial, three of these trials included
7
8 people with acute coronary syndrome (105-107), one included people with heart failure
9
10 (108), one included people with peripheral arterial disease (109) and one included people
11
12 with atrial fibrillation (110) (although in this trial antiplatelet use was not protocol defined).
13
14
15 There was a trend toward a reduction in risk of stroke on meta-analysis (IRR 0.73, 95% CI
16
17 0.53 to 1.01, random effects model) with combination therapy. There was no increased risk
18
19 of intracranial haemorrhage. None of these trials has reported results for the subgroup of
20
21 people with history of stroke and people with stroke or recent stroke were excluded.
22
23
24
25
26
27

28 **Supporting information for consensus statement**

29
30 Overall, we rated the quality of evidence as low due to indirectness; there is no direct
31
32 evidence to support a recommendation for use of antiplatelet therapy combined with a low-
33
34 dose direct oral anticoagulant in people with a history of ischaemic stroke or TIA. In
35
36 particular, it is important to note that people with ischaemic stroke within the past month
37
38 were excluded from the COMPASS trial. However, many people with stroke have a history
39
40 of coronary artery disease or peripheral arterial disease. The effect in people with carotid
41
42 artery disease was also consistent with the main trial results. The use of antiplatelet therapy
43
44 combined with a low-dose direct oral anticoagulant may be an appropriate option for some
45
46 people with a history of ischaemic stroke or TIA, more than one month previously, if they
47
48 have co-existing coronary or peripheral arterial disease and this is being used to optimise
49
50 treatment of these conditions. Note that only rivaroxaban has been studied in this context so
51
52 other DOACs should not be used for this purpose. The panel voted by 12 / 12 members for
53
54 the following consensus statement (supplementary table 2).
55
56
57
58
59
60

Evidence-based Recommendation

-

Quality of evidence: -

Strength of recommendation: -

Expert Consensus Statement

The use of antiplatelet therapy combined with a low-dose direct oral anticoagulant (rivaroxaban) can be considered to optimise treatment of coronary artery disease or peripheral arterial disease in people with a history of ischaemic stroke or TIA more than one month previously. It should not be considered in people with ischaemic stroke or TIA who do not have coronary artery disease or peripheral arterial disease.

PICO Question 11: In people with an embolic stroke of undetermined source (ESUS) does treatment with a direct oral anticoagulant drug compared to an antiplatelet reduce the risk of recurrent stroke?

Analysis of current evidence

The literature search identified 6332 titles and 645 full texts were identified. For this specific PICO question, 2 studies and a total of 12603 participants were included in the qualitative and quantitative synthesis. These two studies were randomised clinical trials comparing a DOAC to an antiplatelet to reduce the risk of stroke in people with ESUS.

1
2
3 The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to
4 Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial is a
5 multicenter, double-blinded, randomised trial which compared rivaroxaban 15 mg once daily
6 with aspirin 100 mg once daily in 7213 people with recent (between 7 days and 6 months)
7 ESUS (111). The mean follow-up duration was 2 years. In this trial, ESUS was defined as non-
8 lacunar ischaemic stroke, not associated with extracranial vessel atherosclerosis causing more
9 than 50% luminal stenosis in arteries supplying the area of ischaemia, or with identified risk
10 factors for a cardiac source of embolism. The use of rivaroxaban did not reduce the risk of
11 recurrent stroke compared to aspirin (HR 1.08, 95% CI 0.87 to 1.34, P=0.47). Major bleeding
12 was increased with rivaroxaban (HR 2.72, 95% CI 1.68 to 4.39, P<0.001). The trial was stopped
13 prematurely because of a lack of benefit on stroke risk and bleeding associated with
14 rivaroxaban.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 The Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the
31 Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate versus Acetylsalicylic
32 Acid in Patients with Embolic Stroke of Undetermined Source (RESPECT ESUS) trial is a
33 multicenter, randomised, double-blind trial which compared dabigatran 150 or 110 mg (for
34 participants aged ≥ 75 years and/or with creatinine clearance 30 to < 50 mL/minute) twice daily
35 with aspirin 100 mg once daily in 5390 people who had experienced an ESUS within the prior
36 3 months (or within the prior 6 months if they had at least one additional vascular risk factor,
37 or if they were aged 18-59 years (20-59 in Japan) and had at least one additional vascular risk
38 factor) (112). The median follow-up duration was 19 months. The definition of ESUS was
39 similar to that used in NAVIGATE. In this trial, dabigatran was not superior to aspirin in
40 preventing stroke (HR 0.85, 95% CI, 0.69 to 1.03, P = 0.10) or ischaemic stroke. Major
41 bleeding was not increased with dabigatran (HR 1.19, 95% CI 0.85 to 1.66).

Results for meta-analysis of all outcomes and GRADE scoring is available in Table 9. On meta-analyses of data from these two trials, there was no difference in the rate of any stroke (OR 0.96, 95% CI 0.75 to 1.22, table 9). The level of certainty was rated as low. There was also no difference in the rate of ischaemic stroke (OR 0.92, 95% CI 0.76 to 1.10, table 9). The rate of haemorrhagic stroke was increased in one trial but on meta-analysis of data from the two trials, the rate of intracranial bleeding (OR 1.87, 95% CI 0.48 to 7.26, table 8) and major bleeding episodes (OR 1.78, 95% CI 0.80 to 3.94, table 8) were not significantly increased (table 9).

Additional information

There is no evidence to suggest DOAC in preference to antiplatelets in people with ESUS as defined in the RESPECT and NAVIGATE trials. Although a DOAC was equally effective with regard to rate of stroke, bleeding risk was increased in one trial and point estimates for any stroke were inconsistent in the two trials. Overall, we rated the quality of evidence as low. Ongoing trials are investigating whether use of serum, ECG or echocardiographic biomarkers can identify people with ischaemic stroke who do benefit from a DOAC (113). However, one trial which adopted this approach, the Apixaban for treatment of embolic stroke of undetermined source (ATTICUS) trial, was stopped early due to futility.

Evidence-based Recommendation

In people with an embolic stroke of undetermined source, we suggest use of antiplatelet therapy and not a DOAC to reduce the risk of recurrent stroke.

Quality of evidence: **Low** ⊕⊕

Strength of recommendation: **Weak against intervention** ↓?

Diabetes Mellitus

PICO Question 12: In people with diabetes mellitus and ischaemic stroke or TIA, does intensive control of glycated haemoglobin level (HbA1c) compared to less intensive HbA1c control reduce the risk of recurrent stroke?

Analysis of current evidence

People with diabetes mellitus are at a two-folds increased risk of stroke and the relative risk of stroke is reported to increase by approximately 15% with each 1% increase in glycated haemoglobin (HbA1c) level (114, 115). Intensive control of blood glucose levels in people with diabetes reduces the risk of microvascular complications such as retinopathy, nephropathy and neuropathy. However, it is less certain whether intensive control lowers risk of major cardiovascular events, including stroke.

Our systematic review literature search identified 1286 titles and 138 full texts were screened. For this specific PICO question, we were unable to identify any randomised controlled trials specifically designed to test the effect of the intensive control of glycaemia on risk of recurrent stroke in people with ischaemic stroke or TIA and diabetes mellitus.

Several trials have reported the effect of intensive glycaemic control on cardiovascular events in other populations of people with diabetes mellitus. The UK Prospective Diabetes Study (UKPDS) included 4209 people with newly diagnosed type 2 diabetes, with a median age of 53 years (116). Only 2% of participants had a history of myocardial infarction and 1% had a history of stroke or TIA on enrolment. Participants were randomly assigned to either a diet policy, with the aim of maintaining a fasting plasma glucose level of < 15 mmol/L, or to an active policy, with the aim of maintaining fasting plasma glucose < 6 mmol/L. Intensive treatment reduced the risk of microvascular complications but not macrovascular disease. Of the 4209 participants, 1704 were overweight; 411 were randomised to conventional treatment,

1
2
3 342 were randomised to intensive treatment with metformin and 951 to intensive control (117).
4
5 Participants treated with metformin had significant reductions in risk of any diabetes-related
6
7 endpoint (32%, 95% CI 13 to 47, $p=0.002$) compared to conventional therapy and lower all
8
9 cause mortality ($p=0.021$) and risk of stroke ($p=0.032$) compared to those treated with other
10
11 glucose lowering drugs.
12
13

14
15 More recently, three randomised trials (118-120) compared intensive glucose control (target
16
17 HbA1c of $< 6\%$ (42 mmol/mol) or 6.5% (48 mmol/mol)) with less intensive control and
18
19 included a greater number of people with a history of cardiovascular disease. Approximately
20
21 40% of participants in the Veterans Affairs Diabetes Trial (VADT) (120) and 35% in the Action
22
23 to Control Cardiovascular Risk in Diabetes (ACCORD) trial had pre-existing cardiovascular
24
25 disease, but the number of people with stroke was not reported. In the Action in Diabetes and
26
27 Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation
28
29 (ADVANCE) trial, 9% of participants had a history of stroke. None of the trials demonstrated
30
31 a reduction in the rate of major cardiovascular events with intensive treatment. A prespecified
32
33 subgroup analysis of data from the ACCORD study suggested that people with no history of
34
35 cardiovascular disease, or with baseline HbA1C $\leq 8\%$ had fewer fatal or non-fatal
36
37 cardiovascular events with intensive therapy. An increase in mortality in the intensive control
38
39 arm led to the premature cessation of the ACCORD study.
40
41
42
43

44
45 A meta-analysis of 7 trials of intensive glucose control versus conventional glucose control
46
47 found that intensive glucose control led to a reduction in major cardiovascular events of 10%
48
49 (RR 0.90, 95% CI 0.85 to 0.96, $p<0.001$). (121) There was no effect on risk of stroke and
50
51 hypoglycaemia was increased. Subgroup analysis demonstrated that people with shorter
52
53 duration of diabetes, a longer duration of follow up and lower baseline HbA1c level had a
54
55 greater benefit from intensive treatment. A further meta-analysis showed a "U" shaped
56
57
58
59
60

1
2
3 association between HbA1c level and mortality, with a HbA1c of 7.5% being associated with
4
5 the lowest HR for all-cause mortality (122).
6
7
8
9

10 **Supporting information to the expert consensus statement**

11
12 There is insufficient evidence to support a recommendation concerning intensive glucose
13
14 control to prevent recurrent stroke in people with previous history of ischaemic stroke or
15
16 TIA. However, many people with stroke will have a new or recent diagnosis of diabetes
17
18 mellitus and all people with diabetes mellitus are at increased risk of microvascular and
19
20 macrovascular complications. People with ischaemic stroke or TIA and diabetes mellitus
21
22 should, like all people with diabetes mellitus, have their glucose control assessed and their
23
24 treatment reviewed in accordance with relevant guidelines for the treatment of diabetes. The
25
26 panel voted by 12 / 12 members for the following consensus statement (supplementary table
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

36 **Evidence-based Recommendation**

37 -

38
39
40 Quality of evidence: -

41
42
43 Strength of recommendation: -
44

47 **Expert Consensus Statement**

48
49 In people with ischaemic stroke or TIA and diabetes mellitus, we support aiming for an HbA1c
50
51 level of <53mmol/mol (7%, 154 mg/dl) to reduce risk of microvascular and macrovascular
52
53 complications. However, this target may need to be individualised based on duration of
54
55 diabetes, age and comorbidities.
56
57
58
59
60

1
2
3 **PICO Question 13:** In people with ischaemic stroke or TIA, does use of pioglitazone
4 compared to no pioglitazone reduce the risk of recurrent stroke?
5
6

7
8 **Analysis of current evidence**
9

10 Pioglitazone is an oral drug from the thiazolidinedione class of peroxisome proliferator-
11 activated receptor γ (PPAR- γ) agonists. It is an insulin sensitising drug and has been shown
12 to reduce the risk of cardiovascular events in people with type 2 diabetes mellitus (123).
13
14


15 Clinical trials of the effect of pioglitazone on cardiovascular events in people with stroke and
16 insulin resistance have also been performed.
17

18
19 Our systematic review literature search identified 1286 titles and 138 full texts were
20 screened. For this specific PICO question, we identified 3 randomised controlled trials (124-
21 126) including 2488 people with ischaemic stroke or TIA treated with pioglitazone and 2492
22 people with ischaemic stroke or TIA treated with control. One study included people with
23 ischaemic stroke or high-risk TIA and insulin resistance (125), one study included people
24 with ischaemic stroke or TIA and insulin resistance or newly diagnosed type 2 diabetes
25 mellitus (126), and one study included people with type 2 diabetes mellitus and
26 macrovascular disease (123) with specific reporting of outcomes for people with previous
27 stroke (124). One additional study included people with hypertension or dyslipidaemia who
28 had either silent cerebral infarcts or carotid arterial disease (the effects of pioglitazone on
29 macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke, PROFIT-
30 J trial) (127). This was not included in our analysis due to the lack of a symptomatic event,
31 but findings were broadly in keeping with those of the included studies.
32
33

34
35 Three studies reported the outcome of any stroke and death (124-126), two reported the
36 outcome of ischaemic stroke (125, 126), haemorrhagic stroke (125, 126), major cardiac
37 events (124, 125) and one trial reported myocardial infarction (125). No trials reported data
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

for the outcomes of cardiovascular death, dementia, intracranial bleeding, major bleeding or functional outcome.

Results for all considered outcomes and GRADE scoring, are available in Table 10. The meta-analysis of three included studies (124-126) showed a significant reduction in risk of any stroke with pioglitazone (HR 0.70, 95% CI 0.52 to 0.95, $p=0.021$, figure 14, table 10). This finding is similar to that of a previous meta-analysis (128) and the effect was consistent across all included studies. The level of certainty was rated as moderate. Use of pioglitazone would be expected to lead to 25 fewer cases of stroke per 1,000 treated. The meta-analysis of two included studies (125, 126) showed a significant reduction in risk of ischaemic stroke with pioglitazone (HR 0.72, 95% CI 0.57 to 0.90, $p=0.005$, table 10). The meta-analysis of two included studies (125, 126) showed no reduction in risk of haemorrhagic stroke with pioglitazone (HR 0.99, 95% CI 0.51 to 1.95, $p=0.984$, table 10). The meta-analysis of two included studies (125, 127) showed no significant reduction in rate of myocardial infarction (OR 0.75, 95% CI 0.53 to 1.06, $p=0.104$). The meta-analysis of three included studies (124-126) showed no significant reduction in risk of death with pioglitazone (HR 0.93, 95% CI 0.75 to 1.15, $p=0.486$). The level of certainty was rated as low.



1
2
3 **Figure 14. Forest plot for the risk of any stroke in trials comparing treatment with**
4 **pioglitazone versus placebo in people with TIA or stroke and diabetes or impaired**
5 **glucose tolerance. Heterogeneity: I-Squared=19.462; Q=2.483**
6
7
8
9

10 11 **Additional information**

12
13 Pioglitazone is not widely used for secondary prevention of stroke, despite the result of the
14
15 Insulin Resistance Intervention After Stroke Trial (IRIS) and other trials. This is largely
16
17 because of reported side effects. Pioglitazone increases risk of weight gain, bone fracture, and
18
19 heart failure. There are also reports of increased risk of bladder cancer. Fracture is a
20
21 particular concern in people with stroke (129). In the IRIS trial the risk of fracture was
22
23 increased with pioglitazone (13.6% vs. 8.8%, HR 1.53, 95% CI 1.24 to 1.89) (130). The
24
25 majority of these fractures were low energy, such as following fall, and just under 50% were
26
27 serious requiring surgery or hospitalisation. The risk of serious fractures was increased by
28
29 1.6% (4.7% vs. 3.1%, HR 1.47, 95% CI 1.03 to 2.09). For comparison, the absolute risk
30
31 reduction for MI and stroke in the IRIS trial was 2.8% giving a number needed to treat of 36
32
33 to prevent one stroke or MI. The corresponding number to harm for serious fracture is 62. An
34
35 increase in fracture was also reported in the PROactive trial (131). Risk of heart failure was
36
37 not increased in the IRIS trial (132) but there was a trend toward an increase in the The
38
39 prospective pioglitazone clinical trial in macrovascular events (PROactive) trial (124). It is
40
41 therefore possible that risk of heart failure will not be increased in people who have insulin
42
43 resistance and no diabetes mellitus, provided there are attempts to identify heart failure and
44
45 oedema, with dose reduction if this is found. The risk of bladder cancer may be increased
46
47 with long-term cumulative exposure and has been demonstrated in meta-analyses of both
48
49 clinical trials (n=9114 participants, OR 1.84, 95%CI, 0.99 to 3.42) and observational studies
50
51 (n=4,846,088, OR 1.13, 95%CI 1.03 to 1.25) (133). The dose of pioglitazone used in trials
52
53 was typically 45 mg daily, but trial protocols allowed lower doses to be used in the event of
54
55
56
57
58
59
60

1
2
3 side effects. It is unclear whether use of lower doses will be effective and cause fewer side
4 effects. Due to the concerns regarding side effects, pioglitazone should only be used after
5 careful consideration of risk of fracture, bladder cancer and heart failure and counselling of
6 the person. It is also important to note that in the IRIS trial, people with TIA were only
7 included if they had motor weakness and aphasia and this should be considered when using
8 pioglitazone in people with insulin resistance and no diabetes mellitus who have has a TIA.
9
10 Overall, we rated the quality of evidence as moderate.
11
12
13
14
15
16
17
18
19
20
21
22
23

Evidence-based Recommendation

24
25
26 In people with ischaemic stroke or TIA, who have insulin resistance or type 2 diabetes mellitus,
27 we suggest pioglitazone be used to reduce risk of recurrent stroke.
28
29

30
31
32
33 Quality of evidence: **Moderate** ⊕⊕⊕

34
35
36 Strength of recommendation: **Weak for intervention** ↑?

Discussion

37
38
39
40
41
42 This guideline document was developed following the GRADE methodology and aims to
43 assist physicians in decision-making regarding pharmacological interventions for the
44 secondary prevention of recurrent stroke after ischaemic stroke or TIA. All recommendations
45 and Expert consensus statements are summarised in Table 10.
46
47
48
49

50
51
52
53
54 Wherever possible, recommendations are provided on the basis of a meta-analysis of
55 randomised controlled trials in defined populations with ischaemic stroke or TIA or from
56 subgroups of these participants. However, such evidence was not always available but there
57
58
59
60

1
2
3 were often studies in primary prevention or in people with other cardiovascular indications.
4
5 In this context, expert consensus statements were formulated and agreed by the MWG. The
6
7 principal outcome for each PICO question was the occurrence of recurrent stroke rather than
8
9 all cardiovascular events. However, other outcomes were rated as critical so were also
10
11 considered when formulating our recommendations.
12
13
14
15
16

17 Broadly, the recommendations for interventions for blood pressure lowering or lipid lowering
18
19 supported a principle of intensive treatment to low targets. In the case of blood pressure
20
21 reduction, this was applicable for all people except in specific groups who may be at an
22
23 increased risk of hypotension. Our guideline also covered use of combination
24
25 antihypertensive treatment, out of office monitoring of blood pressure and addition of novel
26
27 lipid lowering therapies (ezetimibe or PCSK9 inhibitors). However, while these approaches
28
29 may be beneficial in many people after stroke, specific evidence in the setting of secondary
30
31 prevention was often lacking and differences in specific subgroups of stroke remain
32
33 unknown. Developing this evidence should be a key area of future research. This guideline
34
35 has not specifically considered use of fibrate, niacin or bempedoic acid therapy either as an
36
37 add on or in addition to statin therapy. With regard to treatment targets in diabetes mellitus,
38
39 there was very limited evidence for optimal HbA1c targets after stroke, and limited evidence
40
41 for the use of specific drugs. Indeed, although we support current primary prevention
42
43 guidance to optimise control of HbA1c to prevent microvascular targets, the evidence for
44
45 prevention of macrovascular outcomes remains particularly uncertain and should become a
46
47 key focus of future research. It would also be important to clarify whether the reduction in
48
49 stroke seen with GLP1 receptor antagonists in people with diabetes are seen in the secondary
50
51 prevention setting.
52
53
54
55
56
57
58
59
60

1
2
3 There have been a large number of recent studies exploring antithrombotic strategies.
4
5 Although antiplatelet therapy has long been established for the secondary prevention of
6
7 ischaemic stroke, evidence for antiplatelet monotherapy compared to placebo is heavily
8
9 based upon older trials which used aspirin. We did not specifically address the choice of
10
11 antiplatelet but given the limited differences in direct comparisons between aspirin and other
12
13 antiplatelets,(22) we believe that there is likely equivalent benefit from other antiplatelets
14
15 such as clopidogrel. Although recent studies have suggested much of the benefit occurs early
16
17 after initiation of treatment (134), in the absence of trials excluding potential harms of
18
19 stopping antiplatelets, long-term antiplatelet monotherapy is indicated. Long-term dual
20
21 antiplatelet treatment with aspirin and clopidogrel carries an increased risk of harm so we do
22
23 no recommend this regimen. There are numerous ongoing trials in this area so it is likely that
24
25 recommendations will be required to be updated in time.
26
27
28
29
30
31
32

33 The validity of the recommendations and consensus statements in this guidance results from
34
35 the systematic approach, GRADE methodology and for many interventions, the availability
36
37 of high quality randomised controlled trials. However, there are limitations. Firstly, this
38
39 guideline was specifically restricted to the long-term prevention of recurrent stroke, and
40
41 therefore does not apply to decisions in the acute phase of stroke. Secondly, it only applies to
42
43 pharmacological risk factor management after ischaemic events as aetiology-specific
44
45 interventions are covered in separate guidelines, whilst lifestyle factors will be a focus of
46
47 future guidance. We recognise that in the coming years treatment is likely to become more
48
49 specific for the underlying aetiology and that these guidelines may need to be refined.
50
51
52 Thirdly, for many of our PICO questions, there remains limited data in specific populations
53
54 with previous ischaemic stroke or TIA in whom further research is strongly advocated -
55
56 particularly to better define the role of novel antithrombotic strategies, choice of blood
57
58
59
60

1
2
3 pressure lowering drugs, add on therapy to achieve lipid targets and the role of new
4
5 treatments for type 2 diabetes mellitus. Finally, we recognise that female participants are
6
7 often under-represented in clinical trials. We did not specifically address this in our evidence
8
9 appraisal as this has been covered in a recent ESO guideline.
10
11
12
13

14 **Plain language summary**

15
16
17 This guideline is provided for doctors and other clinicians to help them to decide which
18
19 medications should be given to most people after an ischaemic stroke or mini-stroke to
20
21 reduce the risk of future strokes or related problems, such as heart attacks.
22
23

24 Having searched extensively for research published on each of the key questions identified,
25
26 the most important recommendations we have made, based on available evidence, are:
27

- 28 1. People who have had an ischaemic stroke or transient ischaemic attack should be
29 prescribed medication to lower their blood pressure, if this is raised.
30
31
- 32 2. Treatment should aim to achieve a blood pressure level below 130 / 80 mmHg except
33
34 in some people at an increased risk of problems, such as the very elderly, people with
35
36 kidney problems and those with severe narrowing of the large blood vessels to the
37
38 brain.
39
40
- 41 3. People who have had an ischaemic stroke or transient ischaemic attack should be
42
43 prescribed HMGCoA reductase inhibitors (statins) to lower their cholesterol.
44
45
- 46 4. Lipid lowering treatments should aim to keep the low-density cholesterol (bad
47
48 cholesterol) level below 1.8mmol/L (70 mg/dl)
49
50
- 51 5. In the longer term, people who have had an ischaemic stroke or transient ischaemic
52
53 attack, who do not have a specific reason to have a stronger blood thinner, should be
54
55 prescribed aspirin or a similar drug, but only one such medication at a time.
56
57
58
59
60

- 1
- 2
- 3 6. In people with diabetes, or early evidence of it, the anti-diabetic medicine
- 4
- 5 pioglitazone reduces the risk of recurrent stroke, but this should be balanced against
- 6
- 7 an increased risk of broken bones, heart failure and bladder cancer.
- 8
- 9

10 Also, where there was insufficient published research to specifically address the question
11
12 posed, the majority of the working group agreed that:

- 13
- 14 1. Monitoring blood pressure at home is likely to improve blood pressure control.
- 15
- 16 2. When treating blood pressure is indicated, starting treatment with more than one drug
- 17
- 18 is likely to be beneficial for most people.
- 19
- 20 3. In people whose cholesterol level is not controlled with HMGCoA reductase
- 21
- 22 inhibitors (statins), addition of further drugs should be considered.
- 23
- 24 4. In some people with narrowing of blood vessels in the heart or the peripheral arteries,
- 25
- 26 the addition of a low-dose anticoagulant blood thinner (a 'DOAC') to an antiplatelet
- 27
- 28 may be considered but this should not be done to treat their stroke.
- 29
- 30 5. Control of blood sugar to an HbA1c level of <53 mmol/mol (7%, 154 mg/dl) in
- 31
- 32 people with diabetes mellitus and ischaemic stroke or transient ischaemic attack is
- 33
- 34 likely to be beneficial in reducing the risk of cardiovascular events and other
- 35
- 36 complications of diabetes.
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Declarations

Declaration of conflicting interests

All authors have completed a declaration of competing interests and details are available in Supplemental Table 1.

Funding

Funding for the development of these guidelines was provided by the European Stroke Organisation, Basel, Switzerland. The authors did not receive financial support for the development, writing and/or publication of this guideline.

Ethical Approval

Ethical approval was not necessary for the work described in this paper.

Informed consent

Not applicable.

Guarantor

The guarantors of the content of this guideline are Prof Jesse Dawson and Prof Alastair Webb, co-chairs of the Module Working Group.

Contributorship

All members of the MWG were responsible for drafting individual PICO questions. JD and AW wrote the first draft of the manuscript. MTR conducted the statistical analyses. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

The authors would like to thank Yvonne Brüchert for her guidance and organisation throughout writing of the guideline, Anna Noel-Storr and Josh Cheyne for their advice on refining our search strategy.

Supplemental material

Supplemental material for this article is available online.

For Peer Review

Table 1.

List of outcomes included and results of voting. Outcomes shown in bold were rated as critical on round 1 of voting.

Outcome	MWG	MWG	MWG	MWG	MWG	MWG	MWG	MWG	MWG	Mean	Median
	1	2	3	4	5	6	7	8	9	score	score
Ischaemic stroke	9	9	9	9	9	9	9	8	9	8.89	9
Any stroke	9	9	9	9	9	9	9	9	9	9.00	9
Functional outcome	6	9	6	9	8	9	9	8	9	8.11	9
Haemorrhagic stroke	9	9	9	9	7	9	9	8	9	8.67	9
Myocardial infarction	6	9	9	9	4	8	9	7	9	7.78	9
Major cardiovascular events	7	9	9	9	6	8	9	7	9	8.11	9

Death	8	9	9	9	8	8	8	9	9	8.56	9
Cardiovascular death	8	9	9	9	9	9	9	8	9	8.78	9
Intracranial bleeding	7	9	9	6	7	9	9	8	9	8.11	9
Any major bleeding episode	7	7	8	4	7	6	6	9	7	6.78	7
Quality of life	6	5	6	6	6	6	7	6	5	5.89	6
Mild cognitive impairment	5	4	6	5	4	7	6	6	4	5.22	5
Dementia	6	6	6	5	6	8	7	6	6	6.22	6
White matter hyperintensity	3	4	4	5	3	5	5	3	3	3.89	4
Microbleeds	3	4	4	5	3	6	6	4	3	4.22	4
Brain atrophy	3	3	4	5	3	5	5	4	3	3.89	4

Extra-cranial bleeding	7	6	7	4	6	6	6	8	6	6.22	6
Renal failure	5	4	6	4	4	4	4	7	4	4.67	4
Fracture	5	2	3	3	5	2	2	5	2	3.22	3
Falls	5	2	4	3	4	2	3	5	2	3.33	3
Hypoglycaemia	5	3	5	3	5	2	3	5	4	3.89	4

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 2. GRADE evidence profile for PICO question 1: In people with a history of ischaemic stroke or TIA, does blood pressure lowering treatment compared to no blood pressure lowering treatment reduce the risk of recurrent stroke? **CI** = Confidence interval, **OR** = Odds ratio. a = Significant heterogeneity according to I-squared statistic. However, heterogeneity significantly reduced following removal of 1 trial (PROFESS), justifying a ‘Moderate Grading’ for ischaemic stroke. b = Fails to rule out harm (confidence intervals cross 1) c = restricted population sample. NA = not analysed (data for this outcome were not pooled)

Certainty assessment							№ of participants		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	does blood pressure lowering treatment	no blood pressure lowering treatment	Relative (95% CI)	Absolute (95% CI)		
Any stroke												

9	randomi	not	serious ^a	not	not	none	1631/19	1905/19	OR 0.81	17	⊕⊕⊕	CRITIC
	sed	serious		serious	serious		107	215	(0.71 to	fewer	○	AL
	trials						(8.5%)	(9.9%)	0.92)	per		
										1,000	MODE	
										(from	RATE	
										27		
										fewer to		
										7 fewer)		

ischaemic stroke

3	randomi	not	serious ^a	not	very	none	1028/13	1137/13	OR 0.85	12	⊕⊕⊕	CRITIC
	sed	serious		serious	serious ^b		367	334	(0.68 to	fewer	○	AL
	trials						(7.7%)	(8.5%)	1.05)	per		
										1,000	MODE	
										(from	RATE	
										25		

											fewer to 4 more)		
--	--	--	--	--	--	--	--	--	--	--	---------------------	--	--

Haemorrhagic stroke

2	randomi sed trials	not serious	serious ^a	not serious	very serious ^b	none	96/1319 7 (0.7%)	143/132 40 (1.1%)	OR 0.66 (0.38 to 1.13)	4 fewer per 1,000 (from 7 fewer to 1 more)	⊕○○ ○ VERY LOW	CRITIC AL
---	--------------------------	----------------	----------------------	----------------	------------------------------	------	---------------------	-------------------------	---	---	-------------------------	--------------

Major Cardiovascular Events

7	randomi sed trials	not serious	serious ^a	not serious	not serious	none	2309/17 471 (13.2%)	2637/17 470 (15.1%)	OR 0.80 (0.69 to 0.94)	26 fewer per 1,000 (from 42	⊕⊕⊕ ○ MODE RATE	CRITIC AL
---	--------------------------	----------------	----------------------	----------------	----------------	------	---------------------------	---------------------------	---	--	--------------------------	--------------

Cardiovascular death

6	randomi	not	not	not	not	none	589/173	663/173	OR 0.88	4 fewer	⊕⊕⊕⊕	CRITIC
	sed	serious	serious	serious	serious		74	73	(0.78-	per	HIGH	AL
	trials						(3.4%)	(3.8%)	0.99)	1,000		
										(from 8		
										fewer to		
										1 fewer)		

Dementia

2	randomi	not	not	serious ^c	very	none	601/116	626/117	NA	NA	⊕○○○	IMPOR
	sed	serious	serious		serious ^b		75	00			○	TANT
	trials						(5.1%)	(5.4%)			VERY	
											LOW	

Functional outcome

1	randomi	not	not	serious ^c	very	none	400/795	405/838	OR 1.08	20 more	⊕○○	IMPOR
2												
3	sed	serious	serious		serious ^b		(50.3%)	(48.3%)	(0.89 to	per	○	TANT
4	trials								1.32)	1,000	VERY	
5										(from	LOW	
6										28		
7										fewer to		
8										68		
9										more)		
10												
11												
12												
13												
14												
15												
16												
17												
18												
19												
20												
21												
22												
23												
24												
25												
26												
27												
28												
29												
30												
31												
32												
33												
34												
35												
36												
37												
38												
39												
40												
41												
42												
43												
44												
45												
46												

For Peer Review

Table 3. GRADE evidence profile for PICO question 2: In people with a history of ischaemic stroke or TIA starting antihypertensive therapy, does use of out of office blood pressure measurements compared to outpatient clinic measurements provide better long-term control of blood pressure? **CI** = Confidence interval. **MD** = Mean difference. a = fails to rule out harm.

Certainty assessment							№ of participants		Effect		Certain ty	Importa nce
№ of studies	Study design	Risk of bias	Inconsis tency	Indirect ness	Impreci sion	Other conside rations	self- monitor ing	treatme nt as usual	Relative (95% CI)	Absolut e (95% CI)		
Systolic blood pressure												
3	randomi sed trials	not serious	not serious	not serious	very serious ^a	none	276	285	-	MD 2.34 mmHg greater decline (1.45)	⊕⊕○ ○ LOW	CRITIC AL

											fewer to		
											6.13		
											more)		

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 4. GRADE evidence profile for PICO question 3: In people with a history of ischaemic stroke or TIA starting or increasing antihypertensive therapy, does treating to a more intensive (i.e. BP<130/80) versus less intensive (<140/90 mmHg) target reduce the risk of recurrent stroke? CI = Confidence interval. RR = Risk ratio. OR = Odds ratio. a = fails to rule-out harm (confidence intervals cross over 1). b = few events and moderate sample size (optimal information size (OIS) not met). c = fails to rule out benefit or harm (confidence intervals cross over 1). There were no data for dementia and major bleeding outcomes.

Certainty assessment							№ of participants		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	a more intensive (i.e. BP<130/80) target	a less intensive (<140/90 mmHg) target	Relative (95% CI)	Absolute (95% CI)		
Any stroke												

3	randomi	not	not	not	not	none	164/240	207/241	OR	17	⊕⊕⊕⊕	CRITIC
	sed	serious	serious	serious	serious		0 (6.8%)	2 (8.6%)	0.79	fewer	HIGH	AL
	trials								(0.64 to	per		
									0.98)	1,000		
										(from		
										30		
										fewer to		
										2 fewer)		

Ischaemic stroke

3	randomi	not	not	not	very	none	151/219	173/220	OR 0.87	10	⊕⊕○	CRITIC
	sed	serious	serious	serious	serious ^a		3 (6.9%)	1 (7.9%)	(0.69 to	fewer	○	AL
	trials								1.09)	per	LOW	
										1,000		
										(from		
										23		

											31	MODE	
											fewer to	RATE	
											0 fewer)		

Myocardial infarction

3	randomi sed trials	not serious	not serious	not serious	very serious ^a	none	42/2400 (1.8%)	45/2412 (1.9%)	OR 0.94 (0.62 to 1.44)	1 fewer per 1,000 (from 7 fewer to 8 more)	⊕⊕○ ○ LOW	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------	-------------------	---	---	-------------------------	------------------

Death

3	randomi sed trials	not serious	not serious	not serious	very serious ^c	none	138/240 0 (5.8%)	139/241 2 (5.8%)	OR 1.00 (0.78 to 1.28)	0 fewer per 1,000 (from 12	⊕⊕○ ○ LOW	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	---------------------	---------------------	---	---	-------------------------	------------------

											fewer to 15 more)		
--	--	--	--	--	--	--	--	--	--	--	----------------------------------	--	--

Cardiovascular death

3	randomi sed trials	not serious	not serious	not serious	very serious ^a	none	44/2400 (1.8%)	52/2412 (2.2%)	RR 0.86 (0.58 to 1.27)	3 fewer per 1,000 (from 9 fewer to 6 more)	⊕⊕○ ○ LOW	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------	-------------------	---------------------------------------	---	-----------------	--------------

Functional outcome

1	randomi sed trials	not serious	not serious	not serious	very serious ^a	none	49/1501 (3.3%)	49/1519 (3.2%)	OR 0.82 (0.54 to 1.26)	6 fewer per 1,000 (from 15	⊕⊕○ ○ LOW	IMPOR TANT
---	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------	-------------------	---------------------------------------	---	-----------------	---------------

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

											fewer to		
											8 more)		

For Peer Review

Table 5. GRADE evidence profile for PICO question 5: In people with ischaemic stroke or TIA does use of an HMGCoA reductase inhibitor compared to no lipid-lowering therapy reduce the risk of recurrent stroke? CI = Confidence interval. HR = hazard ratio. OR = Odds ratio. There were no data for major bleeding and intracranial bleeding outcomes. A = small effect size and fails to rule out harm (confidence intervals cross over 1). B = study is at high risk of bias. C = small effect size and fails to rule out benefit (confidence intervals cross over 1).

Certainty assessment							No of participants		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	HMGCoA reductase inhibitors	no lipid-lowering therapy	Relative (95% CI)	Absolute (95% CI)		

Any stroke

5	randomised trials	not serious	not serious	not serious	not serious	none	558/508 1 (11.0%)	622/508 8 (12.2%)	HR 0.89 (0.78 to 0.99)	13 fewer per	⊕⊕⊕⊕ High	CRITICAL
---	-------------------	-------------	-------------	-------------	-------------	------	-------------------------	-------------------------	---	---	--------------	----------

3	randomi	not	not	not	not	none	87/4799	56/4790	OR 1.55	6 more	⊕⊕⊕⊕	CRITIC
	sed	serious	serious	serious	serious		(1.8%)	(1.2%)	(1.09 to	per	High	AL
	trials								2.21)	1,000		
										(from 1		
										more to		
										14		
										more)		

Major cardiovascular events

2	randomi	not	not	not	not	none	740/400	895/400	OR 0.78	40	⊕⊕⊕⊕	CRITIC
	sed	serious	serious	serious	serious		6	5	(0.70 to	fewer	High	AL
	trials						(18.5%)	(22.3%)	0.87)	per		
										1,000		
										(from		
										55		
										fewer to		

											17 more)		
--	--	--	--	--	--	--	--	--	--	--	---------------------	--	--

Cardiovascular death

1	randomi sed trials	not serious	not serious	not serious	very serious ^a	none	78/2365 (3.3%)	98/2366 (4.1%)	HR 0.78 (0.58 to 1.06)	9 fewer per 1,000 (from 17 fewer to 2 more)	⊕⊕○ ○ Low	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------	-------------------	---------------------------------------	--	---------------------	------------------

Dementia

1	randomi sed trials	very serious ^b	not serious	not serious	very serious ^a	none	33/793 (4.2%)	33/785 (4.2%)	OR 0.90 (0.79 to 1.03)	4 fewer per 1,000 (from 9	⊕○○○ ○ Very low	IMPOR TANT
---	--------------------------	------------------------------	----------------	----------------	------------------------------	------	------------------	------------------	---------------------------------------	--	------------------------------	-------------------

Table 6. GRADE evidence profile for PICO question 7: In people with ischaemic stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, is the addition of ezetimibe and/or PCSK9-inhibitor superior to HMGCoA reductase inhibitor alone to reduce the risk of recurrent stroke? CI = Confidence interval. HR = hazard ratio. There were no data for major bleeding, dementia, functional outcome and intracranial bleeding outcomes. A = Effect size is small and fails to exclude appreciable harm (confidence intervals cross over 1) b = Effect size is small and fails to exclude benefit (confidence intervals cross over 1). C = Uncertain risk of bias in study.

Certainty assessment							No of participants		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Addition of ezetimibe and/or PCSK9-inhibitor	to HMGCoA reductase inhibitor alone	Relative (95% CI)	Absolute (95% CI)		

								inhibitor					
--	--	--	--	--	--	--	--	------------------	--	--	--	--	--

Any stroke

3	randomised trials	serious	not serious	not serious	very serious ^a	none	149/350 9 (4.2%)	179/346 4 (5.2%)	HR 0.81 (0.64 to 1.04)	10 fewer per 1,000 (from 18 fewer to 2 more)	⊕⊕○ ○ LOW	Critical
---	-------------------	---------	-------------	-------------	---------------------------	------	---------------------	---------------------	---	---	-----------------	----------

ischaemic stroke

2	randomised trials	not serious	not serious	not serious	very serious ^a	none	103/302 2 (3.4%)	130/299 7 (4.3%)	HR 0.72 (0.41 to 1.25)	12 fewer per 1,000	⊕⊕○ ○ LOW	Critical
---	-------------------	-------------	-------------	-------------	---------------------------	------	---------------------	---------------------	---	-------------------------------------	-----------------	----------

											(from 25 fewer to 11 more)		
--	--	--	--	--	--	--	--	--	--	--	--	--	--

Haemorrhagic stroke

2	randomi sed trials	not serious	not serious	not serious	very serious ^b	none	19/3022 (0.6%)	17/2977 (0.6%)	HR 1.11 (0.57 to 2.14)	1 more per 1,000 (from 2 fewer to 6 more)	⊕⊕○ ○ LOW	Critical
---	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------	-------------------	---	--	---------------------	----------

Major Adverse Cardiovascular Events

2	randomi sed trials	not serious	not serious	not serious	not serious	none	352/302 2 (11.6%)	417/297 7 (14.0%)	HR 0.83 (0.72 to 0.96)	22 fewer per	⊕⊕⊕⊕ HIGH	Critical
---	--------------------------	----------------	----------------	----------------	----------------	------	-------------------------	-------------------------	---	---	------------------	----------

1	randomi	serious ^c	not	not	very	none	83/336	85/346	HR 0.96	9 fewer	⊕○○	Critical
	sed trials		serious	serious	serious ^a		(24.7%)	(24.6%)	(0.71 to 1.30)	per 1,000 (from 64 fewer to 61 more)	○ VERY LOW	

Cardiovascular death

2	randomi	not	not	not	very	none	111/302	99/2977	HR 1.11	4 more	⊕⊕○	Critical
	sed trials	serious	serious	serious	serious ^b		2 (3.7%)	(3.3%)	(0.85 to 1.46)	per 1,000 (from 5 fewer to 15 more)	○ LOW	

Table 7. GRADE evidence profile for PICO question 8: In people with ischaemic stroke or TIA, does long-term antiplatelet therapy compared to no antiplatelet treatment reduce the risk of recurrent stroke? **CI** = confidence interval. **OR** = odds ratio. **A** = fails to rule out benefit. Confidence intervals cross 1.0. **b** = fails to rule out harm. Confidence intervals cross 1.0. **c** = limited sample size/no. of events. There were no data for the outcome dementia.

Certainty assessment							№ of participants		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	long-term antiplatelet therapy	no antiplatelet treatment	Relative (95% CI)	Absolute (95% CI)		
Any stroke												
9	randomised trials	not serious	not serious	not serious	not serious	none	681/525 5 (13.0%)	689/446 2 (15.4%)	OR 0.82 (0.73 to 0.92)	24 fewer per 1,000	⊕⊕⊕⊕ High	CRITICAL

4	randomi sed trials	not serious	not serious	not serious	very serious ^a	none	14/1215 (1.2%)	7/1230 (0.6%)	OR 1.93 (0.78 to 4.76)	5 more per 1,000 (from 1 fewer to 21 more)	⊕⊕○ ○ Low	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------	------------------	-------------------------------------	---	---------------------	------------------

Major cardiovascular events

7	randomi sed trials	not serious	not serious	not serious	not serious	none	993/545 8 (18.2%)	997/465 7 (21.4%)	OR 0.78 (0.67 to 0.90)	39 fewer per 1,000 (from 59 fewer to	⊕⊕⊕⊕ High	CRITIC AL
---	--------------------------	----------------	----------------	----------------	----------------	------	-------------------------	-------------------------	---	--	------------------	------------------

											17		
											fewer)		

Myocardial infarction

6	randomi sed trials	not serious	not serious	not serious	not serious	none	127/340 3 (3.7%)	164/342 7 (4.8%)	OR 0.77 (0.61 to 0.98)	11 fewer per 1,000 (from 18 fewer to 1 fewer)	⊕⊕⊕⊕ High	CRITIC AL
---	--------------------------	----------------	----------------	----------------	----------------	------	---------------------	---------------------	---	--	------------------	------------------

Death

10	randomi sed trials	not serious	not serious	not serious	very serious ^b	none	600/588 1 (10.2%)	538/498 8 (10.8%)	OR 0.90 (0.80 to 1.02)	10 fewer per 1,000	⊕⊕○ ○ Low	CRITIC AL
----	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------------	-------------------------	---	---	-------------------------	------------------

											(from 20 fewer to 2 more)		
--	--	--	--	--	--	--	--	--	--	--	------------------------------------	--	--

Cardiovascular death

9	randomi sed trials	not serious	not serious	not serious	very serious ^b	none	305/413 2 (7.4%)	232/333 9 (6.9%)	OR 0.94 (0.79 to 1.13)	4 fewer per 1,000 (from 14 fewer to 9 more)	⊕⊕○ ○ Low	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	---------------------	---------------------	---	--	---------------------	------------------

Any major bleeding episode

3	randomi sed trials	not serious	not serious	not serious	serious ^c	none	42/2850 (1.5%)	17/2861 (0.6%)	OR 2.51 (1.42 to 4.43)	9 more per 1,000	⊕⊕⊕ ○	CRITIC AL
---	--------------------------	----------------	----------------	----------------	----------------------	------	-------------------	-------------------	---	---	--------------	------------------


											(from 2 more to 20 more)	Moderat e	
--	--	--	--	--	--	--	--	--	--	--	-----------------------------------	--------------	--

Functional outcome

2	randomi sed trials	not serious	not serious	not serious	very serious ^a	none	100/172 2 (5.8%)	54/916 (5.9%)	OR 1.01 (0.72 to 1.42)	1 more per 1,000 (from 16 fewer to 23 more)	⊕⊕○ ○ Low	IMPOR TANT
---	--------------------------	----------------	----------------	----------------	------------------------------	------	---------------------	------------------	---	--	---------------------	---------------

Table 8. GRADE evidence profile for PICO question 9: In people with TIA and ischaemic stroke, does treatment with dual antiplatelet therapy for longer than 90 days with aspirin plus clopidogrel or aspirin plus dipyridamole, compared to a single antiplatelet, reduce the risk of recurrent stroke? **CI** = confidence interval. **HR** = hazard Ratio. **OR** = odds ratio. A = significant degree of heterogeneity according to I-squared
 B = fails to rule out harm. Confidence intervals cross 1.0. c = fails to rule out benefit. Confidence intervals cross 1.0. There were no data for the outcome dementia.

Certainty assessment							№ of participants		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	dual antiplatelet therapy for longer than 90 days	Single antiplatelet	Relative (95% CI)	Absolute (95% CI)		



Any stroke

5	randomi	not	serious ^a	not	very	none	1642/19	1720/19	OR 0.90	8 fewer	⊕○○○	CRITIC
	sed	serious		serious	serious ^b		302	268	(0.80 to	per	○	AL
	trials						(8.5%)	(8.9%)	1.02)	1,000	Very	
										(from	low	
										17		

											more to 7 more)		
--	--	--	--	--	--	--	--	--	--	--	--------------------	--	--

Major adverse cardiovascular events

6	randomi sed trials	not serious	serious ^a	not serious	not serious	none	2460/20 665 (11.9%)	2645/20 644 (12.8%)	OR 0.87 (0.78 to 0.97)	15 fewer per 1,000 (from 25 fewer to 4 fewer)	⊕⊕⊕ ○ Moderate	CRITIC AL
---	--------------------------	----------------	----------------------	----------------	----------------	------	---------------------------	---------------------------	---	--	------------------------------	------------------

Myocardial infarction

5	randomi sed trials	not serious	not serious	not serious	very serious ^b	none	360/193 02 (1.9%)	374/192 68 (1.9%)	OR 0.96 (0.83 to 1.11)	1 fewer per 1,000 (from 3	⊕⊕○ ○ Low	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------------	-------------------------	---	--	-------------------------	------------------

											fewer to 1 more)		
--	--	--	--	--	--	--	--	--	--	--	-----------------------------	--	--

Intracranial bleeding

4	randomi sed trials	not serious	not serious	not serious	very serious ^c	none	98/1682 0 (0.6%)	87/1681 1 (0.5%)	OR 1.22 (0.81 to 1.83)	1 more per 1,000 (from 1 fewer to 4 more)	⊕⊕○ ○ Low	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	---------------------	---------------------	---------------------------------------	--	---------------------	------------------

Any major bleeding episode

6	randomi sed trials	not serious	very serious ^a	not serious	very serious ^c	none	700/206 27 (3.4%)	553/206 23 (2.7%)	OR 1.39 (0.95 to 2.02)	10 more per 1,000 (from 1 fewer to	⊕○○○ ○ Very low	CRITIC AL
---	--------------------------	----------------	------------------------------	----------------	------------------------------	------	-------------------------	-------------------------	---------------------------------------	---	------------------------------	------------------

Table 9. GRADE evidence profile for PICO question 11: In people with an embolic stroke of undetermined source does treatment with a DOAC compared to an antiplatelet reduce the risk of recurrent stroke? **CI** = confidence interval. **HR** = hazard Ratio. **OR** = odds ratio. a = considerable heterogeneity according to I-squared. b = fails to rule out harm. Confidence intervals cross 1.0. c = small sample/event size. d = fails to rule out benefit. Confidence intervals cross 1. There were no data for the outcome dementia.

Certainty assessment							№ of participants		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	treatment with a DOAC	antiplatelet	Relative (95% CI)	Absolute (95% CI)		
Any stroke												
2	randomised trials	not serious	serious ^a	not serious	serious ^b	none	348/630 4 (5.5%)	365/629 9 (5.8%)	OR 0.96 (0.75 to 1.22)	2 fewer per 1,000 (from 14	⊕⊕○ ○ low	CRITICAL

											fewer to		
											12		
											more)		

ischaemic stroke

2	randomi	not	not	not	very	none	330/630	359/622	OR 0.92	5 fewer	⊕⊕○	CRITIC
	sed	serious	serious	serious	serious ^b		4 (5.2%)	9 (5.8%)	(0.76 to	per	○	AL
	trials								1.10)	1,000	Low	
										(from		
										13		
										fewer to		
										6 more)		

Haemorrhagic stroke

1	randomi	not	not	not	serious ^c	none	13/3609	2/3604	HR 6.50	3 more	⊕⊕⊕	CRITIC
	sed	serious	serious	serious			(0.4%)	(0.1%)	(1.47 to	per	○	AL
	trials								28.80)	1,000		
										(from 0		

											fewer to	Moderat	
											15	e	
											more)		

Major adverse cardiovascular events

2	randomi	not	not	not	very	none	414/630	427/622	OR 0.97	2 fewer	⊕⊕○	CRITIC
	sed	serious	serious	serious	serious ^b		4 (6.6%)	9 (6.9%)	(0.84 to	per	○	AL
	trials								1.11)	1,000	Low	
										(from		
										10		
										fewer to		
										7 more)		

Myocardial infarction

1	randomi	not	not	not	very	none	17/3609	23/3604	HR 0.74	2 fewer	⊕⊕○	CRITIC
	sed	serious	serious	serious	serious ^b		(0.5%)	(0.6%)	(0.39 to	per	○	AL
	trials								1.38)	1,000	Low	
										(from 4		

											fewer to 2 more)		
--	--	--	--	--	--	--	--	--	--	--	---------------------	--	--

Death

2	randomi sed trials	not serious	not serious	not serious	very serious ^d	none	121/630 4 (1.9%)	110/622 9 (1.8%)	OR 1.10 (0.85 to 1.43)	2 more per 1,000 (from 3 fewer to 7 more)	⊕⊕○ ○ Low	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	---------------------	---------------------	---	--	---------------------	------------------

Cardiovascular death

2	randomi sed trials	not serious	not serious	not serious	very serious ^d	none	37/3903 (0.9%)	24/3904 (0.6%)	OR 1.54 (0.92 to 2.58)	3 more per 1,000 (from 1 fewer to	⊕⊕○ ○ Low	CRITIC AL
---	--------------------------	----------------	----------------	----------------	------------------------------	------	-------------------	-------------------	---	--	---------------------	------------------

										10 more)		
--	--	--	--	--	--	--	--	--	--	---------------------	--	--

Intracranial bleeding

2	randomi sed trials	not serious	very serious ^a	not serious	very serious ^d	none	52/6303 (0.8%)	37/6229 (0.6%)	OR 1.87 (0.48 to 7.26)	5 more per 1,000 (from 3 fewer to 36 more)	⊕○○○ ○ Very low	CRITIC AL
---	--------------------------	----------------	------------------------------	----------------	------------------------------	------	-------------------	-------------------	---------------------------------------	---	--------------------------	--------------

Any major bleeding episode

2	randomi sed trials	not serious	very serious ^a	not serious	very serious ^d	none	139/630 3 (2.2%)	87/6229 (1.4%)	OR 1.78 (0.80 to 3.94)	11 more per 1,000 (from 3 fewer to	⊕○○○ ○ Very low	CRITIC AL
---	--------------------------	----------------	------------------------------	----------------	------------------------------	------	---------------------	-------------------	---------------------------------------	---	--------------------------	--------------

Table 10. GRADE evidence profile for PICO question 13: In people with ischaemic stroke or TIA, does use of pioglitazone compared to no pioglitazone reduce the risk of any recurrent stroke? **CI** = confidence interval. **HR** = Hazard Ratio. **OR** = Odds ratio. a = 2 out of 3 studies at risk of bias but largest study at low risk of bias. b = 1 study at high risk of bias. c = very small sample size. d = 1 study at uncertain risk of bias. E = 1 of 2 studies not exclusively a stroke population. F = confidence intervals crossover 1.00. There were no data for the outcomes cardiovascular death, major bleeding, intracranial bleeding, dementia and functional outcome.

Certainty assessment							№ of participants		Effect		Certain ty	Importa nce
№ of studies	Study design	Risk of bias	Inconsis tency	Indirect ness	Impreci sion	Other conside rations	Pioglitazone	Placebo	Relative (95% CI)	Absolut e (95% CI)		
Any stroke												
3	randomi sed trials	serious ^a	not serious	not serious	not serious	none	158/248 8 (6.4%)	212/249 2 (8.5%)	HR 0.70 (0.52 to 0.95)	25 fewer per 1,000	⊕⊕⊕ ○	CRITIC AL

											(from 40 fewer to 4 fewer)	MODE RATE	
--	--	--	--	--	--	--	--	--	--	--	-------------------------------------	--------------	--

ischaemic stroke

2	randomi sed trials	very serious ^b	not serious	not serious	not serious	none	126/200 2 (6.3%)	175/199 4 (8.8%)	HR 0.72 (0.57 to 0.96)	24 fewer per 1,000 (from 37 fewer to 8 fewer)	⊕⊕○ ○ Low	CRITIC AL
---	--------------------------	------------------------------	----------------	----------------	----------------	------	---------------------	---------------------	-------------------------------------	---	---------------------	------------------

Haemorrhagic stroke

2	randomi sed trials	very serious ^b	not serious	not serious	very serious ^c	none	17/2002 (0.8%)	17/1994 (0.9%)	OR 0.99 (0.51 to 1.95)	0 fewer per 1,000	⊕○○○ ○	CRITIC AL
---	--------------------------	------------------------------	----------------	----------------	------------------------------	------	-------------------	-------------------	-------------------------------------	--	---------------	------------------

										(from 4 fewer to 8 more)	Very low	
--	--	--	--	--	--	--	--	--	--	--------------------------------	-------------	--

Major Adverse Cardiovascular Events

2	randomi sed trials	serious ^d	not serious	not serious	not serious	none	269/242 5 (11.1%)	337/243 5 (13.8%)	HR 0.78 (0.65 to 0.95)	28 fewer per 1,000 (from 47 fewer to 7 fewer)	⊕⊕⊕ ○ MODE RATE	CRITIC AL
---	--------------------------	----------------------	----------------	----------------	----------------	------	-------------------------	-------------------------	---	--	----------------------------------	------------------

Myocardial infarction

2	randomi sed trials	serious ^b	not serious	serious ^e	serious ^f	none	5/234 (2.1%)	4/247 (1.6%)	OR 0.75 (0.53 to 1.06)	4 fewer per 1,000	⊕○○○ ○	CRITIC AL
---	--------------------------	----------------------	----------------	----------------------	----------------------	------	-----------------	-----------------	---	--	---------------	------------------

												(from 7 fewer to 1 more)	VERY LOW	
--	--	--	--	--	--	--	--	--	--	--	--	--------------------------------	-------------	--

Death

3	randomi sed trials	serious ^a	not serious ^f	not serious	serious ^f	none	183/248 8 (7.4%)	197/249 2 (7.9%)	OR 0.93 (0.75 to 1.15)	5 fewer per 1,000 (from 18 fewer to 10 more)	⊕⊕○ ○ LOW	CRITIC AL
---	--------------------------	----------------------	-----------------------------	----------------	----------------------	------	---------------------	---------------------	---	---	-----------------	--------------

Table 11. Synoptic table of all recommendations and expert consensus statements

Recommendation	Expert consensus statement
<p>PICO question 1 In people with a history of ischaemic stroke or TIA, does blood pressure lowering treatment compared to no blood pressure lowering treatment reduce the risk of any recurrent stroke?</p>	
<p>In people with previous ischaemic stroke or TIA, we recommend blood pressure lowering treatment to reduce the risk of recurrent stroke.</p>	
<p>Quality of evidence: High ⊕⊕⊕⊕ Strength of recommendation: Strong for intervention ↑↑</p>	
<p>PICO question 2 In people with a history of ischaemic stroke or TIA starting antihypertensive therapy, does use of out of office blood pressure measurements compared to outpatient clinic measurements provide better long-term control of blood pressure?</p>	
	<p>In people with previous ischaemic stroke or TIA, we support the use of out of office blood pressure measurements wherever feasible, to achieve better long-term control of blood pressure.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PICO question 3: In people with a history of ischaemic stroke or TIA starting or increasing antihypertensive therapy, does treating to a more intensive (i.e. BP<130/80) versus less intensive (<140/90 mmHg) target reduce the risk of recurrent stroke?

In people with previous ischaemic stroke or TIA, we suggest aiming for a blood pressure target of <130/80 mmHg to reduce the risk of recurrent stroke.

Quality of evidence: **Moderate** ⊕⊕⊕

Strength of recommendation: **Weak** for **intervention** ↑?

PICO question 4: In people with a history of ischaemic stroke or TIA starting antihypertensive therapy, does initiation of two blood pressure lowering medications compared to monotherapy reduce the risk of recurrent stroke?

In people with ischaemic stroke or TIA, we support initiation of a combination of two blood pressure lowering drugs to reduce the risk of recurrent stroke, with consideration of monotherapy where there are potential risks of hypotension, such as in frail, elderly people and people with borderline hypertension

PICO question 5: In people with ischaemic stroke or TIA does use of an HMGCoA reductase inhibitor compared to no lipid-lowering therapy reduce the risk of recurrent stroke?

In people with previous ischaemic stroke or TIA we recommend use of a HMGCoA reductase inhibitor to reduce the risk of recurrent ischaemic stroke.

Quality of evidence: **High** ⊕⊕⊕⊕

Strength of recommendation: **Strong for intervention** ↑↑

PICO question 6: In people with ischaemic stroke or TIA does working to an intensive cholesterol treatment target, compared to a less intensive target, reduce the risk of any stroke?

In people with ischaemic stroke or TIA, we recommend aiming for an LDL cholesterol level of <1.8 mmol/l (70 mg/dl) to reduce the risk of major cardiovascular events

Quality of evidence: **Moderate** ⊕⊕⊕

Strength of recommendation: **Strong for intervention** ↑↑

PICO question 7: In people with a previous ischaemic stroke or TIA who do not achieve recommended LDL-C targets despite taking a maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, is the addition of ezetimibe and/or a PCSK9-inhibitor superior to an HMGCoA reductase inhibitor alone to reduce the risk of recurrent stroke?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>In people with ischaemic stroke or TIA who do not achieve the recommended LDL-C targets despite taking maximally tolerated dose of a HMGCoA reductase inhibitor for at least 6 weeks, we support the addition of ezetimibe as an option to reduce the risk of recurrent major cardiovascular events.</p>
<p>PICO question 8: In people with ischaemic stroke or TIA, does long-term antiplatelet therapy compared to no antiplatelet treatment reduce the risk of recurrent stroke?</p>	
<p>In people with previous ischaemic stroke or TIA, we recommend long-term use of antiplatelet therapy to reduce the risk of recurrent stroke.</p> <p>Quality of evidence: Moderate ⊕⊕⊕</p> <p>Strength of recommendation: Strong for intervention ↑↑</p>	
<p>PICO question 9: In people with TIA and ischaemic stroke, does treatment with dual antiplatelet therapy for longer than 90 days with aspirin plus clopidogrel or aspirin plus dipyridamole, compared to a single antiplatelet, reduce the risk of recurrent stroke?</p>	
<p>In people with previous ischaemic stroke or TIA, we recommend against use of dual antiplatelet therapy with aspirin and clopidogrel in the long-</p>	

term and recommend use of single antiplatelet to reduce the risk of recurrent stroke.

Quality of evidence: **Very Low** ⊕

Strength of recommendation: **Weak against intervention** ↓?

PICO question 10: In people with ischaemic stroke or TIA and atherosclerosis, with no other indication for anticoagulation, does antiplatelet therapy combined with a low-dose direct oral anticoagulant compared to antiplatelet therapy alone reduce the risk of recurrent stroke?

The use of antiplatelet therapy combined with a low-dose direct oral anticoagulant (rivaroxaban) can be considered to optimise treatment of coronary artery disease or peripheral arterial disease in people with a history of ischaemic stroke or TIA more than one month previously. It should not be considered in people with ischaemic stroke or TIA who do not have coronary artery disease or peripheral arterial disease.

PICO question 11: In people with an embolic stroke of undetermined source (ESUS) does treatment with a direct oral anticoagulant drug compared to an antiplatelet reduce the risk of recurrent stroke?

In people with an embolic stroke of undetermined source, we suggest use of antiplatelet therapy and not a DOAC to reduce the risk of recurrent stroke.

Quality of evidence: **Low** ⊕⊕

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<p>Strength of recommendation: Weak against intervention ↓?</p>	
<p>PICO question 12: In people with diabetes mellitus and ischaemic stroke or TIA, does intensive control of glycated haemoglobin level (HbA1c) compared to less intensive HbA1c control reduce the risk of recurrent stroke?</p>	
<p>In people with ischaemic stroke or TIA and diabetes mellitus, we support aiming for an HbA1c level of <53mmol/mol (7%, 154 mg/dl) to reduce risk of microvascular and macrovascular complications. However, this target may need to be individualised based on duration of diabetes, age and comorbidities.</p>	
<p>PICO question 13: In people with ischaemic stroke or TIA, does use of pioglitazone compared to no pioglitazone reduce the risk of recurrent stroke?</p>	
<p>In people with ischaemic stroke or TIA, who have insulin resistance or type 2 diabetes mellitus, we suggest pioglitazone be used to reduce risk of recurrent stroke.</p> <p>Quality of evidence: Moderate ⊕⊕⊕</p> <p>Strength of recommendation: Weak for intervention ↑?</p>	

References

1. Béjot Y, Bailly H, Durier J, Giroud M. Epidemiology of stroke in Europe and trends for the 21st century. *Presse Med.* 2016;45(12 Pt 2):e391-e8.
2. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet.* 2005;366(9499):1773-83.
3. Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. *Lancet Neurol.* 2015;14(9):903-13.
4. Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, et al. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. *N Engl J Med.* 2016;374(16):1533-42.
5. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet.* 2010;376(9735):112-23.
6. Heuschmann PU, Kircher J, Nowe T, Dittrich R, Reiner Z, Cifkova R, et al. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. *Eur J Prev Cardiol.* 2015;22(10):1354-62.
7. Norrving B, Barrick J, Davalos A, Dichgans M, Cordonnier C, Guekht A, et al. Action Plan for Stroke in Europe 2018-2030. *Eur Stroke J.* 2018;3(4):309-36.
8. Dawson J, Merwick Á, Webb A, Dennis M, Ferrari J, Fonseca AC. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. *Eur Stroke J.* 2021;6(2):Clxxxvii-cxci.
9. Klijn CJ, Paciaroni M, Berge E, Korompoki E, Körv J, Lal A, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. *Eur Stroke J.* 2019;4(3):198-223.
10. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba L, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. *Int J Stroke.* 2014;9(7):840-55.
11. Fonseca AC, Merwick Á, Dennis M, Ferrari J, Ferro JM, Kelly P, et al. European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack. *Eur Stroke J.* 2021;6(2):Clxiii-clxxxvi.
12. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *Bmj.* 2008;336(7650):924-6.
13. Steiner T, Dichgans M, Norrving B, Aamodt AH, Berge E, Christensen H, et al. European Stroke Organisation (ESO) standard operating procedure for the preparation and publishing of guidelines. *Eur Stroke J.* 2021;6(3):Cxxii-cxxxiv.
14. Thomas J, McDonald S, Noel-Storr A, Shemilt I, Elliott J, Mavergames C, et al. Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews. *J Clin Epidemiol.* 2021;133:140-51.
15. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *Bmj.* 2011;343:d5928.
16. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj.* 2019;366:l4898.
17. Harrison JK, Reid J, Quinn TJ, Shenkin SD. Using quality assessment tools to critically appraise ageing research: a guide for clinicians. *Age Ageing.* 2017;46(3):359-65.
18. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol.* 2011;64(4):380-2.

19. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360(9349):1903-13.
20. Kaplan RC, Tirschwell DL, Longstreth WT, Jr., Manolio TA, Heckbert SR, LeValley AJ, et al. Blood pressure level and outcomes in adults aged 65 and older with prior ischemic stroke. *J Am Geriatr Soc*. 2006;54(9):1309-16.
21. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet*. 2001;358(9287):1033-41.
22. Heart Outcomes Prevention Evaluation Study I, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342(3):145-53.
23. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. *N Engl J Med*. 2008;359(12):1225-37.
24. Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group. *JAMA*. 1974;229(4):409-18.
25. Post-stroke antihypertensive treatment study. A preliminary result. *Chin Med J (Engl)*. 1995;108(9):710-7.
26. Gayet JL. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens*. 2003;21(9):1771; author reply -2.
27. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group. *Stroke*. 1993;24(4):543-8.
28. Eriksson S, Olofsson B, Wester P. Atenolol in Secondary Prevention after Stroke.
29. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. *J Hypertens*. 2005;23(12):2157-72.
30. Marti Masso JF, Lozano R. Nifedipine in the prevention of cerebral infarction. *Clin Ther*. 1990;12(4):344-51.
31. Zonneveld TP, Richard E, Vergouwen MD, Nederkoorn PJ, de Haan R, Roos YB, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. *Cochrane Database Syst Rev*. 2018;7(7):Cd007858.
32. Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A, et al. Blood Pressure Reduction and Secondary Stroke Prevention: A Systematic Review and Metaregression Analysis of Randomized Clinical Trials. *Hypertension*. 2017;69(1):171-9.
33. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. *Lancet*. 2021;397(10285):1625-36.
34. McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMINSR randomized clinical trial. *Jama*. 2014;312(8):799-808.
35. Kerry SM, Markus HS, Khong TK, Cloud GC, Tulloch J, Coster D, et al. Home blood pressure monitoring with nurse-led telephone support among patients with hypertension and a history of stroke: a community-based randomized controlled trial. *CMAJ*. 2013;185(1):23-31.
36. Davison WJ, Myint PK, Clark AB, Kim LG, Wilson EC, Langley M, et al. Does self-monitoring and self-management of blood pressure after stroke or transient ischemic attack improve control? TEST-BP, a randomized controlled trial. *Am Heart J*. 2018;203:105-8.
37. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42(34):3227-337.
38. Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. *PLoS Med*. 2017;14(9):e1002389.

- 1
- 2
- 3
- 4 39. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. Blood-pressure
- 5 targets in patients with recent lacunar stroke: the SPS3 randomised trial. *Lancet*. 2013;382(9891):507-
- 6 15.
- 7 40. Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, et al. Different systolic blood
- 8 pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention
- 9 After Stroke--Blood Pressure) randomised controlled trial. *BMJ*. 2016;352:i708.
- 10 41. Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, et al. Effect of Standard
- 11 vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and
- 12 Meta-analysis. *JAMA Neurol*. 2019;76(11):1309-18.
- 13 42. Park JM, Kim BJ, Kwon SU, Hwang YH, Heo SH, Rha JH, et al. Intensive blood pressure control
- 14 may not be safe in subacute ischemic stroke by intracranial atherosclerosis: a result of randomized
- 15 trial. *J Hypertens*. 2018;36(9):1936-41.
- 16 43. Rothwell PM, Howard SC, Spence JD, Carotid Endarterectomy Trialists C. Relationship
- 17 between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease.
- 18 *Stroke*. 2003;34(11):2583-90.
- 19 44. Bejot Y, Duloquin G, Graber M, Garnier L, Mohr S, Giroud M. Current characteristics and early
- 20 functional outcome of older stroke patients: a population-based study (Dijon Stroke Registry). *Age*
- 21 *Ageing*. 2021;50(3):898-905.
- 22 45. Yan J, Zheng K, Liu A, Cheng W. The Impact of Cognitive Function on the Effectiveness and
- 23 Safety of Intensive Blood Pressure Control for Patients With Hypertension: A post-hoc Analysis of
- 24 SPRINT. *Front Cardiovasc Med*. 2021;8:777250.
- 25 46. Graber M, Garnier L, Mohr S, Delpont B, Blanc-Labarre C, Vergely C, et al. Influence of Pre-
- 26 Existing Mild Cognitive Impairment and Dementia on Post-Stroke Mortality. The Dijon Stroke Registry.
- 27 *Neuroepidemiology*. 2020;54(6):490-7.
- 28 47. Pendlebury ST, Rothwell PM, Oxford Vascular S. Incidence and prevalence of dementia
- 29 associated with transient ischaemic attack and stroke: analysis of the population-based Oxford
- 30 Vascular Study. *Lancet Neurol*. 2019;18(3):248-58.
- 31 48. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of
- 32 hypertension in patients 80 years of age or older. *N Engl J Med*. 2008;358(18):1887-98.
- 33 49. Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, et al. Effect of Intensive
- 34 Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke:
- 35 A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial.
- 36 *Circulation*. 2016;133(6):584-91.
- 37 50. Beddhu S, Rocco MV, Toto R, Craven TE, Greene T, Bhatt U, et al. Effects of Intensive Systolic
- 38 Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease:
- 39 A Secondary Analysis of a Randomized Trial. *Ann Intern Med*. 2017;167(6):375-83.
- 40 51. MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, et al.
- 41 Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of
- 42 Hypertension: A Double-Blind Randomized Controlled Trial. *J Am Heart Assoc*. 2017;6(11).
- 43 52. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel
- 44 blocker amlodipine combination as an initial treatment strategy for hypertension control
- 45 (ACCELERATE): a randomised, parallel-group trial. *Lancet*. 2011;377(9762):312-20.
- 46 53. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy
- 47 in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*.
- 48 2009;122(3):290-300.
- 49 54. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial
- 50 monotherapy and combination therapy and hypertension control the first year. *Hypertension*.
- 51 2012;59(6):1124-31.
- 52 55. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of
- 53 antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. *J*
- 54 *Hypertens*. 2010;28(7):1584-90.
- 55
- 56
- 57
- 58
- 59
- 60

56. Conn VS, Ruppap TM, Chase JA, Enriquez M, Cooper PS. Interventions to Improve Medication Adherence in Hypertensive Patients: Systematic Review and Meta-analysis. *Curr Hypertens Rep.* 2015;17(12):94.
57. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J.* 2018;39(33):3021-104.
58. Castellano JM, Sanz G, Penalvo JL, Bansilal S, Fernandez-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. *J Am Coll Cardiol.* 2014;64(20):2071-82.
59. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet.* 2010;375(9718):906-15.
60. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ.* 2009;338:b1665.
61. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. *Circulation.* 2011;123(15):1611-21.
62. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med.* 2008;359(23):2417-28.
63. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, et al. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. *Hypertens Res.* 2015;38(1):89-96.
64. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. *J Hypertens.* 2011;29(8):1649-59.
65. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative G. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet.* 2004;363(9411):757-67.
66. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med.* 2006;355(6):549-59.
67. Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, et al. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study. *EBioMedicine.* 2015;2(9):1071-8.
68. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. *Circulation.* 1999;99(2):216-23.
69. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, et al. Pravastatin therapy and the risk of stroke. *N Engl J Med.* 2000;343(5):317-26.
70. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. *Stroke.* 2008;39(2):497-502.
71. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, 3rd, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. *Stroke.* 2007;38(12):3198-204.
72. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Bejot Y, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. *N Engl J Med.* 2020;382(1):9.
73. Hosomi N, Kitagawa K, Nagai Y, Nakagawa Y, Aoki S, Nezu T, et al. Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke). *Stroke.* 2018;49(4):865-71.
74. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N Engl J Med.* 2018;379(22):2097-107.

- 1
- 2
- 3 75. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added
- 4 to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med.* 2015;372(25):2387-97.
- 5 76. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab
- 6 and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med.* 2017;376(18):1713-22.
- 7 77. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, et al. Prevention of
- 8 Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in
- 9 IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). *Circulation.*
- 10 2017;136(25):2440-50.
- 11 78. Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, et al. Effect of Alirocumab on
- 12 Stroke in ODYSSEY OUTCOMES. *Circulation.* 2019;140(25):2054-62.
- 13 79. Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, et al. Stroke Prevention
- 14 With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin
- 15 in High-Risk Patients With Stable Atherosclerosis. *Stroke.* 2020;51(5):1546-54.
- 16 80. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et
- 17 al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from
- 18 170,000 participants in 26 randomised trials. *Lancet.* 2010;376(9753):1670-81.
- 19 81. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et
- 20 al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:
- 21 meta-analysis of individual data from 27 randomised trials. *Lancet.* 2012;380(9841):581-90.
- 22 82. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia
- 23 (AITIA study). *Thromb Haemost.* 1979;41(1):135-41.
- 24 83. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. *N Engl J Med.*
- 25 1978;299(2):53-9.
- 26 84. Bousser MG, Eschwege E, Haguenaux M, Lefaucconnier JM, Thibault N, Touboul D, et al. "AICLA"
- 27 controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral
- 28 ischemia. *Stroke.* 1983;14(1):5-14.
- 29 85. Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, et al.
- 30 Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A
- 31 Danish cooperative study. *Stroke.* 1983;14(1):15-22.
- 32 86. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. *Stroke.*
- 33 1987;18(2):325-34.
- 34 87. European Stroke Prevention Study. ESPS Group. *Stroke.* 1990;21(8):1122-30.
- 35 88. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-
- 36 TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry.* 1991;54(12):1044-54.
- 37 89. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after
- 38 cerebrovascular ischaemic events. The SALT Collaborative Group. *Lancet.* 1991;338(8779):1345-9.
- 39 90. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention
- 40 Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci.*
- 41 1996;143(1-2):1-13.
- 42 91. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian
- 43 American Ticlopidine Study (CATS) in thromboembolic stroke. *Lancet.* 1989;1(8649):1215-20.
- 44 92. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al. Cilostazol stroke prevention
- 45 study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. *J Stroke*
- 46 *Cerebrovasc Dis.* 2000;9(4):147-57.
- 47 93. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death,
- 48 myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
- 49 Antiplatelet Trialists' Collaboration. *Bmj.* 1994;308(6921):81-106.
- 50 94. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and
- 51 clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic
- 52 attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet.*
- 53 2004;364(9431):331-7.
- 54
- 55
- 56
- 57
- 58
- 59
- 60

95. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med.* 2006;354(16):1706-17.
96. Investigators SPS, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. *The New England journal of medicine.* 2012;367(9):817-25.
97. Group ES, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet.* 2006;367(9523):1665-73.
98. Sacco RL, Diener H-C, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med.* 2008;359(12):1238-51.
99. Greving JP, Diener HC, Reitsma JB, Bath PM, Csiba L, Hacke W, et al. Antiplatelet Therapy After Noncardioembolic Stroke. *Stroke.* 2019;50(7):1812-8.
100. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N Engl J Med.* 2017;377(14):1319-30.
101. Perera KS, Ng KKH, Nayar S, Catanese L, Dyal L, Sharma M, et al. Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. *JAMA Neurol.* 2020;77(1):43-8.
102. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet.* 2018;391(10117):219-29.
103. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, et al. Stroke Outcomes in the COMPASS Trial. *Circulation.* 2019;139(9):1134-45.
104. Galli M, Capodanno D, Benenati S, D'Amario D, Crea F, Andreotti F, et al. Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis. *Eur Heart J Cardiovasc Pharmacother.* 2021.
105. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J.* 2011;32(22):2781-9.
106. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet.* 2009;374(9683):29-38.
107. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med.* 2012;366(1):9-19.
108. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghide M, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. *N Engl J Med.* 2018;379(14):1332-42.
109. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. *N Engl J Med.* 2020;382(21):1994-2004.
110. Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. *N Engl J Med.* 2020;383(18):1735-45.
111. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. *N Engl J Med.* 2018;378(23):2191-201.
112. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. *N Engl J Med.* 2019;380(20):1906-17.
113. Kamel H, Longstreth WT, Jr., Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, et al. The Atrial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. *Int J Stroke.* 2019;14(2):207-14.

- 1
2
3 114. Folsom AR, Rasmussen ML, Chambless LE, Howard G, Cooper LS, Schmidt MI, et al. Prospective
4 associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The
5 Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Diabetes Care*. 1999;22(7):1077-83.
6 115. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes
7 in trials of oral diabetes medications: a systematic review. *Arch Intern Med*. 2008;168(19):2070-80.
8 116. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional
9 treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective
10 Diabetes Study (UKPDS) Group. *Lancet*. 1998;352(9131):837-53.
11 117. Effect of intensive blood-glucose control with metformin on complications in overweight
12 patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*.
13 1998;352(9131):854-65.
14 118. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of intensive
15 glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358(24):2545-59.
16 119. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose
17 control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358(24):2560-72.
18 120. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and
19 vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360(2):129-39.
20 121. Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, et al. Effects of intensive glucose control
21 on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. *Ann Med*.
22 2010;42(4):305-15.
23 122. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of
24 HbA(1c) in people with type 2 diabetes: a retrospective cohort study. *Lancet*. 2010;375(9713):481-9.
25 123. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al.
26 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study
27 (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
28 *Lancet*. 2005;366(9493):1279-89.
29 124. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of
30 pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive
31 (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). *Stroke*. 2007;38(3):865-73.
32 125. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after
33 Ischemic Stroke or Transient Ischemic Attack. *N Engl J Med*. 2016;374(14):1321-31.
34 126. Tanaka R, Yamashiro K, Okuma Y, Shimura H, Nakamura S, Ueno Y, et al. Effects of Pioglitazone
35 for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed
36 Diabetes: The J-SPIRIT Study. *J Atheroscler Thromb*. 2015;22(12):1305-16.
37 127. Yoshii H, Onuma T, Yamazaki T, Watada H, Matsuhisa M, Matsumoto M, et al. Effects of
38 pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke:
39 the PROFIT-J study. *J Atheroscler Thromb*. 2014;21(6):563-73.
40 128. Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for Secondary Stroke Prevention:
41 A Systematic Review and Meta-Analysis. *Stroke*. 2017;48(2):388-93.
42 129. Kanis J, Oden A, Johnell O. Acute and long-term increase in fracture risk after hospitalization
43 for stroke. *Stroke*. 2001;32(3):702-6.
44 130. Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al. Pioglitazone and Risk
45 for Bone Fracture: Safety Data From a Randomized Clinical Trial. *J Clin Endocrinol Metab*.
46 2017;102(3):914-22.
47 131. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of
48 pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. *Drug Saf*.
49 2009;32(3):187-202.
50 132. Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, et al. Heart Failure After
51 Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus
52 Treated With Pioglitazone. *Circulation*. 2018;138(12):1210-20.
53
54
55
56
57
58
59
60

- 1
2
3 133. Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, et al. Pioglitazone and bladder cancer risk: a
4 systematic review and meta-analysis. *Cancer Med.* 2018;7(4):1070-80.
5 134. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of aspirin on risk and
6 severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course
7 analysis of randomised trials. *Lancet.* 2016;388(10042):365-75.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review